

Advancing Development & Manufacturing

Pharmaceutical Technology

© PharmTech.com

EUROPE



APIs, EXCIPIENTS, AND MANUFACTURING 2019



 **CPHI** worldwide®

5 - 7 November 2019 | Frankfurt, Germany

Supelco® analytical products. Exquisite accuracy. Every time.


MERCK

Maintaining your high standards in pharma analysis and pharma QC requires analytical products you can rely on, along with the right documentation and expertise.

That's why the entire range of Supelco® analytical products, which includes reference materials, solvents and columns, is exquisitely developed to ensure you reliably achieve your analytical goals and comply with guidelines and regulations. So for work that hits the mark every time, choose Supelco® analytical products.

For more information, please visit:
SigmaAldrich.com/SuccessReplicated

Pharmaceutical
Technology
EUROPE
FOR PERSONAL, NON-COMMERCIAL USE



Merck, the vibrant M and Supelco are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources.

© 2019 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

The Life Science Business
of Merck operates as
MilliporeSigma in the US
and Canada.

Supelco®
Analytical Products

PharmTech Group

Editorial Director

Rita Peters
RPeters@mmhgroup.com

PharmTech Europe

Editor

Felicity Thomas
FThomas@mmhgroup.com

Senior Editor

Agnes Shanley
AShanley@mmhgroup.com

Managing Editor

Susan Haigney
SHaigney@mmhgroup.com

Manufacturing Editor

Jennifer Markarian
JMarkarian@mmhgroup.com

Science Editor

Feliza Mirasol
FMirasol@mmhgroup.com

Assistant Editor

Lauren Lavelle
LLavelle@mmhgroup.com

Art Director

Dan Ward

Publisher

Michael Tracey
MTracey@mmhgroup.com

Sales Manager

Linda Hewitt
Tel. +44 (0) 151 353 3520
LHewitt@mmhgroup.com

Senior Sales Executive

Stephen Cleland
Tel. +44 (0) 151 353 3647
SCleland@mmhgroup.com

Sales Operations Executive

Barbara Williams
BWilliams@mmhgroup.com

VP & Managing Director,

MJH Life Sciences™:
Dave Esola

C.A.S.T. Data and List Information

Michael Kushner
MKushner@mmhgroup.com

MJH Life Sciences™

Chairman and CEO
Mike Hennessy, Sr

Vice Chairman

Jack Lepping

President

Mike Hennessy, Jr

Chief Strategy Officer & President,
Agency Services

George Glatcz

Chief Accounting Officer

David Brennan

Chief Financial Officer

Neil Glasser, CPA/CFE

Executive Vice President,
Operations

Tom Tolvé

Senior Vice President, Content

Silas Inman

Senior Vice President, I.T. &
Enterprise Systems

John Moricone

Senior Vice President,
Development & Enterprise
Systems

JP Uva

Senior Vice President, Audience

Generation & Product Fulfillment
Joy Puzzo

Vice President, Human Resources

& Administration
Shari Lundenberg

Vice President, Business

Intelligence
Chris Hennessy

Vice President, Corporate Branding

& B2B Marketing
Amy Erdman

Executive Creative Director,

Creative Services
Jeff Brown

Published by

MJH Life Sciences™
Sycamore House, Suite 2
Lloyd Drive
Cheshire Oaks
Cheshire
Ch65 9HQ, United Kingdom
Tel. +44 151 353 3500
Fax +44 151 353 3601

Editorial: All submissions will be handled with reasonable care, but the publisher assumes no responsibility for safety of artwork, photographs, or manuscripts. Every precaution is taken to ensure accuracy, but the publisher cannot accept responsibility for the accuracy of information supplied herein or for any opinion expressed.

Subscriptions:

Pharmaceutical Technology Europe is free to qualified subscribers in Europe.

To apply for a free subscription, or to change your name or address, go to
PharmTech.com, click on Subscribe, & follow the prompts.

To cancel your subscription or to order back issues, please email your
request to fulfil@hcl.com, putting PTE in the subject line.

Please quote your subscription number if you have it.

Reprints: Reprints of all articles in this issue and past issues are available (500 minimum).

Licensing and Reuse of Content: Contact our official partner, Wright's Media, about available usages, license fees, and award seal artwork at Advanstar@wrightsmedia.com for more information. Please note that Wright's Media is the only authorized company that we've partnered with for MJH Life Sciences™ materials.

Copyright 2019 MJH Life Sciences™ (UK) all rights reserved.

No part of the publication may be reproduced in any material form (including photocopying or storing it in any medium by electronic means and whether or not transiently or incidentally to some other use of this publication) without the written permission of the copyright owner except in accordance with the provisions of the Copyright Designs & Patents Act (UK) 1988 or under the terms of the license issued by the Copyright License Agency's 90 Tottenham Court Road, London W1P 0LP, UK.

Applications for the copyright owner's permission to reproduce any part of this publication outside of the Copyright Designs & Patents Act (UK) 1988 provisions, should be forwarded in writing to Permission Dept.
Alexa Rockenstein, arockenstein@mmhgroup.com.

Warning: the doing of an unauthorized act in relation to a copyright work may result in both a civil claim for damages and criminal prosecution.



APIs, Excipients, and Manufacturing 2019

ENCAPSULATION

s4 Advancements in Encapsulation Technology

Nicolas Madit and Matt Richardson

UNDERSTANDING API PROPERTIES

s8 Uncovering Hidden Risks in Solid-State API Properties

Jonathan Loughrey

QUALITY

s12 Perspectives on Quality Attributes of Drug Products Containing Nanomaterials

Anthony Hickey, Emmanuel Akala, Lawrence Block, John Hammond,
Munir Hussain, Brent Kleintop, Nancy Lewen, June Liang, Jolyon
Mitchell, Norbert Maurer, Myke Scoggins, Timothy Shelbourn,
Thomas Tice, Katherine Tyner, Eloise Welfare, and Kahkashan Zaidi

ADDITIVES

s16 Additives and Processing Aids in Pharmaceutical Excipients

George Collins, Katherine Ulman, Douglas G. Muse, Elizabeth Tocce,
Chris Moreton, Priscilla Zawislak, and Joseph Zeleznik

STANDARDS AND REGULATIONS

s21 Regulating Excipient Quality, No Mean Feat

Felicity Thomas

FORMULATION

s24 How Excipient Type Influences Self-Emulsifying Drug Delivery

Frank Romanski

ASEPTIC MANUFACTURING

s29 Annex 1 Considerations for Fill/Finish

Jürgen Metzger

PROCESS OPTIMIZATION

s32 Integrating Powder Characterization into Raw Material Selection and Process Optimization

Todd Mollner and Jamie Clayton

VIEWPOINT: API PROCUREMENT

s35 Planning a Successful API Procurement Strategy

Selwyn Lustman, Lina Cogan, and Hamilton J. Lenox

CPHI WORLDWIDE 2019 PREVIEW

s38 Market Dynamics Drive the Agenda for CPhI Worldwide

s42 Ad Index

On the Cover: xyz - Stock.adobe.com; Dan Ward



Advancements in Encapsulation Technology

Technological advancements can address the formulation and dissolution challenges of HPMC polymers.

Nicolas Madit is senior business development manager, and **Matt Richardson** is business development manager, both at Capsule Delivery Solutions, Lonza Pharma & Biotech.

With an ever-increasing range of hard capsule polymers to choose from, optimizing performance and efficacy is a priority in the drug development process. As many new chemical entities (NCEs) are moisture-sensitive, formulators must look to technologies and alternative processes to stabilize these formulations and improve drug performance. In particular, capsules that utilize the excipient polymer hydroxypropyl methyl cellulose (HPMC) have seen increasing global use for their stability against challenges that typically afflict gelatine capsules.

HPMC has been well-vetted in the market as a pharmaceutical excipient long before its use as a capsule polymer. To that end, it has attained regulatory approval in all major pharmaceutical markets. HPMC-based capsules, in general, are the preferred polymer for formulators as a result of lower moisture content compared to gelatine capsules, which makes them ideal to encapsulate moisture-sensitive and hygroscopic APIs.

While first-generation HPMC capsules presented formulators the challenge of differing *in-vitro* dissolution profiles, an innovation in the manufacturing process of HPMC capsules has provided reproducible, pH-independent *in-vitro* dissolution performance comparable to gelatine capsules on the market. Today, HPMC capsules are the preferred alternative dosage form to gelatine capsules as both a valuable and effective development tool, providing formulators the flexibility to encapsulate a broader range of drug products and formulations.

Formulation challenges caused by moisture

In formulation, careful attention must be paid to moisture and its impact on the overall final dosage form. Moisture, usually derived from the environment and atmosphere, can be detrimental to the physical stability of the capsule and/or chemical stability of the API.

Many APIs and excipients are either moisture-sensitive or hygroscopic. By absorbing water from the capsule or environment, compounds may chemically degrade or change morphology or physical characteristics. As such, the capsule selection offering a lower moisture content to maintain robustness and protect the API would be greatly beneficial. Gelatine capsules contain an average moisture content of 13–16%,

whereas HPMC capsules have a lower average moisture content of 5–8%.

When hygroscopic compounds interact with gelatine capsules, the loss of moisture can lead to brittleness of the capsule shell. Gelatine relies on water for plasticity, while HPMC capsules do not. Therefore, HPMC capsules can sustain mechanical stability at a lower percent relative humidity (% RH) range (**Figure 1**) and are better suited for moisture-sensitive and hygroscopic APIs (1).

As a basic requirement to ensure the efficacy of a drug and patient safety, the API must remain stable in the finished dosage form until the end of its shelf life. The stability of gelatine capsules relies on an environment maintained at 35–65% RH and 15–25 °C. Some formulations cannot remain stable in these conditions, which can lead to degradation of the drug or changes in the formulation over time. In a study of moisture diffusion of hard gelatine capsules and HPMC capsules, the moisture uptake of gelatine capsules was higher at all levels of % RH (2). The study found that HPMC would appear to be a better choice in protecting hygroscopic capsule contents from moisture-induced deterioration even when both types of capsules are stored properly.

Another study observed HPMC and gelatine shells, filled with a moisture-sensitive API, in inductively sealed bottles such that the primary source of moisture is the capsule shells. The API filled in HPMC capsules only showed 2% degradation versus 8% in gelatine over 18 months. HPMC shells demonstrated less hydrolysis caused from the moisture content contained in the capsule shells, meaning increased shelf life of moisture-sensitive compounds encapsulated in HPMC capsules and continued safety and efficacy of the drug.

Diving into dissolution

Efficacy generally refers to the product's stability in dissolution performance once it is ingested. There are various types of commercial two-piece HPMC capsules developed using both different formulations and manufacturing processes, providing distinct *in-vitro* and *in-vivo* characteristics. HPMC capsules were first developed with the use of a gelling system to create a two-piece


hard capsule. Those first-generation HPMC capsules relied on secondary gelling agents (e.g., carrageenan, gellan gum) and ionic gel promoters (e.g., potassium acetate, potassium chloride) that cause variability in dissolution rates depending on the pH and ionic strengths of the dissolution media. Traditional HPMC capsules did not dissolve consistently, and as expected, the encapsulated compound would be released inconsistently or belatedly.

A common gelling system, kappa-carrageenan and potassium salts, used in first-generation HPMC capsules showed enhanced resistance to dissolution when in the presence of foods with potassium and calcium cations (3). The delays in dissolution time resulting from that interaction in the stomach were shown in an *in-vitro* study in which caffeine-filled traditional HPMC capsules were tested in a number of dissolution media.

At pH 1.2 *United States Pharmacopeia (USP)*, the normal acidity level of the stomach, 90% of the caffeine dissolved within approximately 15 minutes (**Figure 2**). The addition of 2 g/L of potassium chloride (KCl) resulted in no dissolution after 15 minutes, and a caffeine dissolution between 70% and 80% took more than one hour. As KCl content increased, the dissolution was delayed further; KCl content of 9 g/L had a dissolution rate of 10% in 45 minutes. The study also tested HPMC capsules in an alternative environment of simulated milk fluid, in which results showed similar delays in release and low dissolution rates thereby suggesting a difference in fed- and fasted-state dissolution.

HPMC capsules also demonstrate stable dissolution performance at high temperatures for short periods of time (4). After being heated at several temperatures—the highest reaching 90 °C—for 24 hours, the disintegration performances of hard gelatine and hypromellose capsules were tested in three media: pH 1.2 *USP* buffer, demineralized water, and pH 6.8 *USP* buffer. In this test, hard gelatine capsules sustained expected dissolution performance until they were heated at and above 60 °C, at which point they became deformed, partly molten, and stuck together. In general, thermal stability up to 60 °C is not always the case for gelatine capsules,

Figure 1: Effect of moisture content on capsule shell brittleness for gelatine and hypromellose capsules. RH is relative humidity.



as there is dependence on humidity, and gelatine may demonstrate chemical instability within that temperature range. HPMC capsules remained functional and demonstrated no change in dissolution performance across all temperatures and media tested.

Another challenge that affects dissolution presented by gelatine is hard-gelatine cross-linking. Cross-linking can cause considerable changes within *in-vitro* dissolution profiles. The phenomenon often occurs when the capsule is exposed to chemicals incompatible with gelling agents or high temperatures. Dissolution studies have shown HPMC polymers are unaffected by cross-linking derived from either high heat and humidity or cross-linking chemical promoters like formaldehyde (**Figure 3**).

Thermo-gelation process enables next-generation HPMC hard capsules

Advancements in HPMC capsules have led to the widespread use of second-generation HPMC capsules—those without secondary gelling agents, making the risk of inconsistent dissolution avoidable. Due to the lack of a gelling agent, these advanced capsules provide improved and parallel dissolution performance compared to first-generation HPMC and gelatine capsules, respectively, and are able to mitigate issues of cross-linking, demonstrating enhanced stability when gelatine and other HPMC capsules may be less compatible.


Manufactured through a uniquely developed thermo-gelation process, Vcaps Plus capsules are made without

a gelling system altogether, which is still commonly found in many marketed HPMC capsules. Dissolution studies have shown that performance variability is often noted when a gelling system is incorporated in the HPMC matrix, but a more consistent performance is afforded when the capsule is comprised of only HPMC and water as ingredients.

A human bioequivalence study of Vcaps Plus (Lonza Capsugel) capsules, with 24 patients, demonstrated equivalent performance to hard gelatin capsules with three BDCCS Class 1 biomarkers—acetaminophen, acetylsalicylic acid, and caffeine—further demonstrating its excellent performance while similar studies done on HPMC capsules which do contain a gelling system show greater intra-patient variability as well as a notable difference in onset time of drug absorption (T_{lag}) (4).

The study used Excedrin extra strength caplets to compare the dissolution rate of a fixed-dose combination compressed caplet containing three different rapidly-absorbed drugs over-encapsulated with either gelatine capsules or HPMC capsules using a thermo-gelation process. The *in-vitro* dissolution results confirmed that the APIs had slower release from the over-encapsulated product than from the unencapsulated caplets. As observed, an onset in the release of active of 5 minutes for the gelatine and 10 minutes for HPMC over-encapsulated dosage form versus the unencapsulated caplet. However, all three forms achieved a 95% release within 30 minutes.

Figure 2: Caffeine *in-vitro* dissolution in hypromellose capsules produced with gelling systems vs. hypromellose capsules produced without gelling systems (Vcaps Plus capsules). Where USP stands for United States Pharmacopeia, JP2 stands for Japanese Pharmacopoeia—Disintegration Test Fluid No. 2.



Despite a short lag time generated by encapsulation, the use of either gelatine and HPMC capsules did not result in a significant difference in *in-vivo* pharmacokinetics in 24 human subjects. These results suggest that drug release and absorption from gelatine and HPMC capsules for the three model compounds are equivalent.


A study utilizing a Sotax disintegration test with an automated end point compared the disintegration times of Vcaps Plus capsules with gelatine capsules (5). Similarly, the test showed that the former capsules have no significant difference in disintegration time compared to gelatine capsules and will disintegrate in less than 15 minutes per requirements of major pharmacopoeia.

Further optimization of dissolution performance can be achieved with absolute pH and ionic media independence. Advanced HPMC capsules are effective for pharmaceutical manufacturers looking to optimize product performance. Given the gelatine-like appearance, dissolution, and machinability performance, formulators can begin development with HPMC capsules or more seamlessly switch from gelatine capsules to HPMC capsules with reduced costs and delay in repetitive stability testing.

Conclusion

With the ability to protect encapsulated APIs against moisture, HPMC capsules are an ideal

Figure 3: Dissolution of acetyl-para-aminophenol (APAP) in human chorionic gonadotropin (HGC) and hypromellose shell 2 after one-week exposure to lactose spiked with formaldehyde.



formulation tool when gelatine capsules are incompatible. Moreover, HPMC capsules without gelling systems have been designed to overcome inconsistent dissolution performance presented by the interaction between gelling agents and the dissolution environment. Increased stability of the formulation and reproducible *in-vitro* dissolution help pharmaceutical manufacturers' drug product and encapsulated API remain effective and safe throughout shelf life, and the capsule acts as an optimal solution to consistently deliver the drug in the patient's body.

References

1. D. Murachanian, *Journal of GXP Compliance*, 14 (3) 31–42 (2010).
2. A.S. Braham, F. Tewes, and A.M. Healy, *Int. J. Pharm.*, 478 (2) 796–803 (2015).
3. M.S. Ku, et al., *Int. J. Pharm.*, 416 (1) 16–24, (2011).
4. M.S. Ku, et al., *Int. J. Pharm.*, 386 (1–2) 30–41 (2010).
5. D. Cadé, "Vcaps Plus Capsules: A New HPMC Capsule for Optimum Formulation of Pharmaceutical Dosage Forms," capsugel.com, Capsugel in-house study (2012). **PTE**

MOVE PRODUCTS NOT CONTAMINATION



ELIMINATE CART WHEEL DISINFECTION

Cart top slides onto a new, clean base.

Cart base transporting products coming from **GRADE C** area.

LINE OF DEMARCATION
SEPARATING ROOM CLASSIFICATIONS

- Reduces safety concerns with cleaning.
- Provides the ability to steam sterilize bases & wheels.
- Eliminates the over use of disinfectants, reducing corrosion and pitting.
- Reduces garment contamination and gloves ripping.
- Available in 3 styles: Mircro Cart, Can & Bottle Cart, and Tray Cart. Custom Built Carts also available.

Cart base ready to move products going to a **GRADE A** area.

For more information visit: sterile.com/cart2core



vai

Veltek Associates, Inc.
15 Lee Boulevard
Malvern, PA 19355
Patents: sterile.com/patents

STERILE.COM



Uncovering Hidden Risks in Solid-State API Properties

An understanding—during early development—of the solid form landscape of an API can enhance product quality and manufacturing processes.

Jonathan Loughrey
is head of screening,
Cambrex Edinburgh.

In the manufacture of small-molecule APIs, developers must be wary of the phenomenon of polymorphism, where an organic molecule can adopt a number of crystalline forms. Controlling the solid form of an API is a critical step in ensuring manufacturing control, as the uncontrolled occurrence of polymorphs can affect the filtration and drying characteristics during the synthesis, as well as the drug's formulation, long-term stability, and solubility properties.

The drug ritonavir had to be temporarily withdrawn from the market following launch, after a less-soluble polymorph that caused the drug to have much reduced therapeutic effect was discovered (1). Production of the drug was halted until a new formulation of the drug was developed, causing disruption to patients, as well as having financial consequences for manufacturers.

A number of strategies can be employed to control the polymorphic form during manufacturing. These strategies include seeding—where a small amount of the desired polymorphic form is introduced to promote crystallization of that form via nucleation—and screening for and choosing an appropriate solvent to perform the crystallization step. In another method, crystallization control, the crystallization is designed with the use of a quality-by-design (QbD) procedure and monitored using process analytical tools (PAT) to ensure it is robust and predictable during changes to temperature, solvent composition/anti-solvent addition, or agitation rates.

In all cases, the key step in delivering the desired solid form of an API is understanding and characterizing the polymorphic landscape to identify and predict phase transitions.

Hydrate formation and associated risks

Due to the ubiquitous nature of water vapour, hydrates are often very stable under ambient conditions. It is estimated that up to 75% of all pharmaceuticals are affected by hydrate formation (2), which has a direct effect on the physical properties of the API, and subsequently how a drug will eventually perform *in vivo*, in terms of stability, solubility, and bioavailability.

Hydrate formation can become apparent at any stage of development or manufacturing operations; specific steps can be taken to avoid this, but only once the hydrate has been understood. The risk of hydrate formation is increased upon formation of ionic species (salts) or a molecule having polar functional groups such as carbonyl, hydroxyl, or amino functionalities.

Studies to predict polymorphism and hydrate formation are possible using computational methods and correlate well with experimental data (3–5). Standard techniques for characterization are shown in **Table I**.

Once the studies are complete, the results offer crucial structural data on the solid forms, allowing crystallization development to be undertaken to enhance particle morphologies and give better control over the solid forms as the product progresses through scale up and development. Avoiding hydrate formation allows efficient large-scale manufacturing, yielding an API with good handling and processing properties, as well as being optimized for the formulation of patient-ready dose forms.

Case study: Locating and understanding hydrated forms of an API

As discussed, facile hydrate formation can drastically alter the processability, stability, and aqueous solubility of a given API, and this example shows how an API was fully characterized to allow the development of a reliable method for synthesis, avoiding an undesirable hemi-hydrated form that was uncovered during a polymorph screening project.

Upon arrival, the single-crystal structure of the preferred polymorphic form, Form 1, was determined wherein the structure was found to be close-packed with normal density (1.3 g/cm³) and no solvent/water accessible voids. Similarly, thermal gravimetric analysis (TGA) confirmed the anhydrous, non-solvated nature of the form, while analysis by dynamic vapour sorption (DVS) at 25 °C, showed minor hysteresis with a maximum mass uptake of 0.95 wt.% at 90% relative humidity (RH), confirming its status as a developable form (**Figure 1**).



Table I: Analytical techniques for physical and structural analysis of polymorphs.

Techniques	Method(s)
Thermal analysis	Thermal gravimetric analysis (TGA) Differential scanning calorimetry (DSC) Variable temperature X-ray powder diffraction (VT-XRPD)
Hygroscopicity measurements	Dynamic vapour sorption (DVS) Variable humidity X-ray powder diffraction (VH-XRPD)
Critical water activity studies/maps	
Kinetic and thermodynamic solubility	Van 't Hoff Plots
Intrinsic dissolution rates (IDR)	High-performance liquid chromatography (HPLC)
<i>In-situ</i> characterization techniques	Infrared spectroscopy (IR) Near-infrared spectroscopy (NIR) Raman spectroscopy
Morphology	Polarized light microscopy (PLM) Scanning electron microscopy (SEM)
X-ray diffraction	Single crystal X-ray diffraction (SC-XRD) X-ray powder diffraction (XRPD)

During further screening, it became apparent that the changes in water activity could promote morphological changes in the API. As shown in **Figure 2**, when slurried in alcohol:water systems of varying water activity (A_w), the morphology changed from an irregular morphology at 0.1 A_w to a plate-like morphology at 0.3 A_w and finally, to a rod-like morphology at 0.9 A_w . It was noted that at 0.5 A_w , a mixed morphology was apparent, comprised of both plates and rods, which indicated that competing growth kinetics that could be exploited to maximize processability and filterability of the API at a later stage of the development programme.

Investigation into the solid form recovered at high water activity (0.9 A_w) by X-ray powder diffraction (XRPD) showed that this was a novel form, herein denoted as Form 2, and found to be hemi-hydrated when characterized by TGA and Karl Fisher titration.

To properly de-risk the novel, hemi-hydrated Form 2, a suitable sample was characterized by DVS, which showed that the input Form 2 was stable between 10–90% RH, but dehydrated rapidly below 10% RH, forming a novel anhydrous species, Form 3 (**Figure 3**). When the relative humidity at 25 °C was cycled back to 40% RH, Form 3 prevailed, but rapidly rehydrated when cycled to 50% RH. These observations highlighted significant risk with development of the hemi-hydrated species for two reasons: the structure of the hemi-hydrated form collapsed on dehydration,

Figure 1: Dynamic vapour sorption (DVS) isotherm plot of Form 1. RH is relative humidity.**Figure 2: Light micrographs showing morphological control.**

forming a novel, anhydrous form; and upon rehydration, Form 3 collapsed and became amorphous prior to re-crystallizing to Form 2.

Variable humidity X-ray diffraction confirmed this observation. It was seen that within the window 30–70% RH, re-hydration of Form 3 to Form 2 was facile, and predictable, but proceeded via an increase in amorphous content (**Figure 4**), significantly heightening the risk associated with the development

of either Forms 2 or 3. Based on the evidence, it was clear that the anhydrous Form 1 was the most desirable form for further development. However, to understand the conditions under which Form 1 would prevail, competitive slurry experiments were performed on Form 1 (anhydrous), Form 2 (hemi-hydrate) and Form 3 (anhydrous) in process relevant media. These experiments clearly showed Form 1 to be the preferred,

Figure 3: Dynamic vapour sorption DVS Isotherm Plot of Form 2. RH is relative humidity.




Figure 4: Variable humidity X-ray powder diffraction 2 θ diffractograms (Black: Form 3; Blue: Form 2). RH is relative humidity.




Figure 5: SEM images of Form 1 before (top 6 images) and after (bottom 3 images) morphology development.



thermodynamic form under anhydrous conditions for further development.

Despite being the thermodynamically preferred form, a key

disadvantage for the development of Form 1 was found to be its poor particle morphology. During the screening studies, however, morphological

differences were noticed due to competing crystal growth kinetics in systems containing varying water activity. Using the non-random two-liquid (NRTL) equation and measured water activity, a detailed hydration map was investigated across multiple organic solvents; it was found that the morphology of Form 1 was greatly improved using small volume aliquots of water in ICH class 3 solvents (e.g., 0.5 Aw = 95 % isopropanol : 5 % water, % v/v) to minimize the risk of hemi-hydrate formation. This vast improvement in particle morphology was exemplified by scanning electron microscopy (SEM) as shown in **Figure 5**.


The significant increase in particle size coincided with an increase in crystallinity and improvement in material handling properties, specifically with respect to flowability and bulk density. Once the preferred Form 1 was isolated with improved particle morphology, crystallization development was able to be undertaken to carry the compound forward by thoroughly investigating the metastable zone and understanding the critical process parameters of the isolation step directly from solution using a design of experiments approach.

De-risking the solid form landscape of an API early in development is of utmost importance to ensure success as a viable drug candidate. By controlling the solid-state properties of an API, downstream processing and manufacture will benefit from predictable stability, solubility, and bioavailability, minimizing development timelines and cost. This case study exemplified the risk that hidden hydrates may pose to process development, but when the solid form landscape is thoroughly investigated and stringently controlled, significant advantages in particle control may be realized.

References

1. J. Bauer, et. al., *Pharmaceutical Research*, 18 (6) 859–866 (2001).
2. L. Infantes, et. al., *CrystEngComm*, 5 (8) 480–486 (2003).
3. D. E. Braun, et. al., *Cryst. Growth Des.*, 14 (4), 2056–2072 (2014).
4. D. E. Braun, et. al., *Mol. Pharmaceut.*, 12 (8), 3069–3088 (2015).
5. S.L. Price, et. al., *Chem. Commun.*, 44, 7076–7077 (2016). **PTE**

Quality. Proven




Ophthalmics




Nasal formulations




Topical formulations



Oral formulations




Wound care




Vaccines




Personal care



Medical devices



Contraception formulations



Veterinary products



Antiseptic agents



Diagnostic testing and other analysis

Regulations don't compromise. Neither can you.

It's not only the authorities who demand proven quality, purity and traceability every time. You do. That's why our Quats are manufactured to the strictest cGMP regulations, and not a single ingredient is delivered without meeting your own uncompromising standards. Whether it is **Benzalkonium Chloride**, **CTAB**, **Cetrimide** or **Strong Cetrimide Solution** for ophthalmic, nasal sprays, topicals, oral products or medical devices, our cGMP Quats can be used as excipients or APIs across a variety of applications. We know that your business depends upon absolute confidence in your supplier – so we've built our business to deliver the reliability you need. **Excellence. Multiplied.**

Learn more about our full range of pharma grade Quats at novonordiskpharmatech.com

Visit us at

 **CPhI**worldwide®


   

Stand #42D32 (HALL 4.2)

**Novo Nordisk
Pharmatech A/S**



Perspectives on Quality Attributes of Drug Products Containing Nanomaterials



In this article, the contents of a stimulus article produced by the joint subcommittee of the USP Expert Committees on Dosage Forms, Physical Analysis, and Excipients and relevant comments from a workshop session are summarized.

Anthony Hickey, Emmanuel Akala, Lawrence Block, John Hammond, Munir Hussain, Brent Kleintop, Nancy Lewen, June Liang, Jolyon Mitchell, Norbert Maurer, Myke Scoggins, Timothy Shelbourn, Thomas Tice, Katherine Tyner, Eloise Welfare, all members of the Joint Subcommittee of the United States Pharmacopeia Expert Committees on Dosage Forms, Chemical Analysis, Physical Analysis, and Excipients; and **Kahkashan Zaidi**, United States Pharmacopeia*, kxz@usp.org

*To whom all correspondence should be addressed.

The current interest in nanotechnology and its application to the medical field has historical precedent. Initial products employed general physical chemistry of colloids to produce stable drug suspensions and improve bioavailability. The later introduction of liposomes began the evolution to today's more sophisticated, and potentially revolutionary, new technologies accompanying the rapid growth in biotechnology product opportunities, notably including targeted drug delivery products.

The term 'nanomaterials' describes materials that have features or structures that exist on the nanoscale in any of the three spatial dimensions. The large numbers of formulations containing nanomaterials that are currently under development, under review, or have already received approval from the US Food and Drug Administration (FDA) emphasizes the need to identify important properties of these formulations and methods of measurement of their properties to ensure quality and performance. FDA has offered guidance to nanomaterials (1). The document emphasizes the need to evaluate materials with any dimension in the nanoscale (1–100 nm) as well as products showing size-dependent properties with dimensions up to 1000 nm.

Nanomaterials may be added to the dosage form to confer a desired physicochemical or mechanical properties; for example, colloidal silicon dioxide (i.e., fumed silica), which acts as a glidant in tablet manufacture. Despite achieving the desirable properties, undesirable effects of excipients should also be considered. A guidance for industry from FDA addresses the needs of this class of nanomaterials (2).

Structure of nanomaterial

When considering the composition of specific nanomaterial formulations a variety of structures can be considered including: carbon nanotubes (3,4); dendrimers (5); drug (6) and inorganic (7) nanoparticles; liposomes (8), micelles (9,10), nanobubbles (11);

nanoemulsions (12), nanofibres (13–15), polymeric (16,17) (natural and synthetic); and solid-lipid nanoparticles (18). Characterization of nanomaterial is presented below.

Products may initially contain nanomaterials, or this state of matter might result from post-market changes to existing products through processes to create nanostructures. Over a period of 10 years, spanning the turn of the Millennium, products for cancer (doxorubicin and paclitaxel), anaemia (sodium ferric gluconate complex), macular degeneration (pegaptanib sodium), tear production (cyclosporine), aspergillosis (amphotericin B), acromegaly (lanreotide acetate), and hypercholesterolaemia (fenofibrate) as liposomes, inorganic, and polymeric (natural and synthetic, nanotubes, nanocrystal emulsions, and micelles (19) were prepared. Many of the aforementioned formulations have yet to be translated to commercialized products. However, it should be anticipated that many will find their way onto the market.

Applications of nanomaterials

Nanotechnology can be employed to modify the biopharmaceutical disposition, bioavailability, and biodistribution, of a drug substance. Desired characteristics such as solubility and the route of administration of the drug substance dictate how critical the size and structure of nanomaterials are to their function.

Rapidly degrading/dissolving nanoparticles exhibit near instantaneous loss of morphology and release drug substance for absorption and distribution, whereas nanoparticles that remain intact for extended time periods may play a role in the pharmacological effect of the drug in the central compartment due to their size and/or structure. Following oral administration, a rapidly dissolving, readily bioavailable nanocrystal drug substance/formulation is known to exhibit different pharmacokinetics compared to that exhibited by a

formulation containing the drug substance of larger particle size. Similarly, differences in integrity of nanoparticles, rapid or slow dissolution, will influence systems administered by the parenteral route. Hydrophobic systems are routinely used for intravenous injection and inhalation. Synthetic and natural polymeric nanoparticles forming rigid structures have been used primarily for intramuscular depot delivery. Nanocrystals have been delivered in oral solid dosage forms for gastrointestinal (GI) absorption.

Generalizing critical quality attributes from one product to the next to accommodate the needs of quality by design is difficult (19). Nevertheless, key variables should be identified, and their impact characterized and controlled to support quality metrics. Considerations with respect to products containing nanomaterials have been reviewed (20) and risk has been characterized (21).

General texts on the safety of nanomaterials exist (22). Specific considerations for drug products containing nanomaterials relate to the kinetics of dissolution and disposition following administration and the fate of components of the materials. Safety considerations for pharmaceutical nanomaterials in a regulatory context have been described (13,16,20,22).

The risk associated with the drug alone exposure is a baseline consideration for a nanoparticle formulation. It can be assumed that rapidly dissolving nanoparticles carry the same risk as molecular drug presentation, because the existence of the nanomaterial is transient. Long residence-time nanoparticles potentially modulate the risk. Limiting the release rate of the drug may reduce the risk of adverse effects. In contrast, the risk may be elevated beyond that of the drug and components alone if accumulation or concentration in specific physiological compartments occurs. Parenterally administered inorganic particles (e.g., gold and silver), micelles, and liposomes are among the drug nanomaterial combinations that might present an

elevated risk. Oral administration of nanoparticles may affect the residence time of nanoparticles in the GI tract as a desirable drug delivery function but may also raise the potential for elevated risk.

Evaluation of nanomaterials

Every drug product requires the assessment of quality parameters to grant safety and efficacy to be released for human and veterinary use. Yet, nanomaterials add an additional layer of complexity to the formulation steps. For example, the processes of mixing/blending, filling (solid and liquid), compression, and lyophilization require consideration of the nanomaterial state and its preservation throughout

Every drug product requires the assessment of quality parameters to grant safety and efficacy to be released for human and veterinary use.

manufacturing. Performance quality tests follow the dosage form characterization and route of administration considerations set forth in the *United States Pharmacopeia (USP)* and regulatory guidance. If the nanomaterial is essential to the function of the dosage form, additional specific tests may be requested.

A comprehensive approach to the measurement of physicochemical characteristics includes the following:

- Aerodynamic particle size distribution using *USP* <601> for micro-aggregated nanoparticles and <1601> nebulized particles or low-pressure impactor for nanoparticle aerosols (23)
- Composition and structure using atomic absorption spectroscopy and photon-correlation spectroscopy
- Dissolution and *in-vitro* release using microdialysis (24), fibre optic probe (25), infrared (26) and Raman (27) spectroscopy
- Encapsulation efficiency
- Particle size using scanning and transmission electron microscopy (SEM and TEM) and

- atomic force microscopy (AFM)
- Particle distribution using photon correlation spectroscopy, small angle X-ray and neutron scattering (SAXS and SANS);
- Purity, shape using SEM, TEM, AFM, SAXS and SANS, and solubility
- Surface area using gas adsorption, surface properties using X-ray photoelectron spectroscopy, secondary ion mass spectroscopy, zeta potential, and freeze fracture SEM
- Physical stability.

Critical quality attributes (CQA) and regulatory considerations.

It should be noted that FDA and the European Medicines Agency (EMA) do not formally use the term 'nanomedicines' and EMA has

only recently acknowledged it.

Nanomedicines in combination products are subject to the overarching FDA guidance and then assessed on a case-by-case basis. There are no combinations in the EMA lexicon so it is important to meet with the regulatory agency early to address requirements.

FDA has guidance that is overarching, class-specific, and product-specific. The International Pharmaceutical Regulators Forum is developing a map of relevant guidance and regulations.

Methods and specific product considerations. An example of specific consideration is the use of an oral formulation with and without nanomaterial. In this case, FDA would conduct a risk assessment and track this information over time as it would for products not containing nanomaterials. Each product would be managed on a case-by-case basis, and the complete package would be evaluated regarding the materials and their physicochemical properties, and how they impact quality. This

approach ensures that methods are appropriate to the way the product is characterized. This approach necessitates that CQAs are defined and have adequate characterization methods, stability testing, and a risk management plan.

As bioequivalence implies drug bioavailability from the drug product, the extent to which the unique contribution of nanomaterials as a subcomponent should be evaluated depends on the dosage form. For example, drug release information from drug products containing nanomaterials may be required by FDA. Consequently, dissolution testing may be a tool that can be used for evaluation. The analysis of dimers (or other polymers) may require a different method and gel

Conclusion

The most prominent drug formulations comprising nanoparticles are liposomes, drug nanocrystals, and iron colloids as illustrated by the earlier mentioned extensive description. The most frequently measured characteristic—particle size distribution—and the DLS and high-resolution imaging techniques employed will be the initial focus of the USP in preparing general chapters to address these topics.

A strategy will then be adopted to continue to introduce general chapters as new delivery systems come to market and to increase the compendium of important physicochemical properties measured. In this regard zeta-

The most frequently measured characteristic—particle size distribution—and the DLS and high-resolution imaging techniques employed, will be the initial focus of the USP in preparing general chapters to address these topics.

electrophoresis has been considered.

There may be subtle differences in the way in which dynamic light scattering (DLS) measures particles based on their material properties, hard versus soft, for example. FDA is also working with the International Organization for Standardization (ISO), American Society for Testing and Materials (ASTM) International, and USP to develop and disseminate DLS standards. It is important to recognize which materials DLS would appropriately characterize. Complementary methods to DLS seem to focus on microscopy.

Data collection and collation.

An informatics strategy for the collection and collation of data is required to characterize CQAs of the nanomaterial in the product. It is difficult to identify biological endpoints attributable to the nanomaterial. Measures of efficacy and safety should be derived from the studies of the drug product.

potential measurement has been identified as an important method for which a general chapter should be developed. In addition, the expert committee with the most relevant expertise to prepare these chapters will be alerted to the need and tasked with generating the document (e.g., physical analysis, dosage forms or excipients).

There is a need for clarity on CQAs, their measurement and impact on product quality, safety, and efficacy.

References

1. FDA, *Guidance for Industry Considering Whether an FDA-Regulated Product Involves the Application of Nanotechnology* (Rockville, MD, June 2014).
2. FDA, *Guidance for Industry, Non-Clinical Studies for the Safety Evaluation Of Pharmaceutical Excipients* (Rockville, MD, May 2005).
3. A. Bianco, N. Kostarelos, and M. Prato, *Curr. Opin. Chem. Bio.*, 9 (6) 674–679 (2005).

4. M. Wolin, et al., *J. Gastrointest. Cancer*, 47 (4) 366–374 (2016).
5. B. Nanjwade, et al., *Eur. J. Pharm. Sci.*, 38 (3) 185–196 (2009).
6. T.-L. Chang, et al., *Front. Chem. Sci. Eng.*, 9 (1) 1–14 (2015).
7. T. Kim and T. Hyeon, *Nanotechnol.*, 25 (1) 012001 (2014).
8. B.S. Pattni, V.V. Chapin, and V.P. Torchilin, *Chem. Rev.*, 115 (19) 10938–10966 (2015).
9. S.R. Croy and G.S. Kwon, *Curr. Pharm. Des.*, 12 (36) 4669–4684 (2006).
10. C.J.H. Porter, N.L. Trevaskis, and W.N. Charman, *Nat. Rev. Drug Discov.*, 6 (3) 231–248 (2007).
11. J. Ma, et al., *Mol. Med. Rep.*, 12 (3) 4022–4028 (2015).
12. M. Jaiswal, R. Duhde and P.K. Sharma, *3 Biotech*, 5 (2) 123–127 (2015).
13. D.H. Reneker, et al., *J. Applied Phys.*, 87 (9) 4531–4546 (2000).
14. S. Thakkar and M. Misra, *Eur. J. Pharm. Sci.*, 107 148–167 (2017).
15. G. Vannuruswamy, et al., *J. Bioact. Compat. Polym.*, 30 (5) 472–489 (2015).
16. A. Kumari, S.K. Yadav, and S.C. Yadav, *Colloids and Surf. B*, 75 (1) 1–18 (2010).
17. R. Dinarvand, et al., *Int. J. Nanomed.*, 6 877–895 (2011).
18. R.H. Müller, K. Mäder, and S. Kohla, *Eur. J. Pharm. Biopharm.*, 50 (1) 161–177 (2000).
19. K.M. Tyner, et al., *Nanomed. Nanobiotechnol.*, 7 (5) 640–654 (2015).
20. R.H. Müller, K. Mäder, and S. Kohla, *Eur. J. Pharm. Biopharm.*, 50 (1) 161–177 (2000).
21. A.S. Narang, R.K. Chang, and M.A. Hussain, *J. Pharm. Sci.*, 102 (11) 3867–3882 (2013).
22. U. Vogel, et al., *Handbook of Nanosafety: Measurement, Exposure and Toxicology* (Elsevier-Academic Press, 2014).
23. M. Marjamäki, et al., *J. Aerosol Sci.*, 31 (2) 249–261 (2000).
24. J. Shen and D.J. Burgess, *Drug Del. Transl. Res.*, 3 (5) 409–415 (2013).
25. B. Van Eerdenbrugh, D.E. Alonzo, and L.S. Taylor, *Pharm. Res.*, 28 (7) 1643–1652 (2011).
26. C.L. McFearin, J. Sankaranarayanan, and A. Amutairi, *Anal. Chem.*, 83 (10) 3943–3949 (2011).
27. R.L. McCreery, M. Fleischmann, and P. Hendra, *Anal. Chem.*, 55 (1) 146–148 (1983). **PTE**



**BDS
Manufacture**

**Single-use
Platform**

**Aseptic
Fill/Finish**

**Vials &
Syringes**

**Clinical
& Commercial**

Protected.



People, Products & Possibilities

Everyone wants to be protected. With Emergent BioSolutions, you can be sure you are. They have a proven track record as a world-class provider of contract manufacturing services, for both bulk drug substances and sterile injectable drug products. They are dedicated to one simple mission: to protect and enhance life.

See how Emergent protects lives.

ebsi.com/CDMO

800-441-4225 | CDMO@ebsi.com



Additives and Processing Aids in Pharmaceutical Excipients

This article seeks to encourage continued dialogue among stakeholders to achieve consensus regarding excipient additives and processing aids.

This article expands on a previous publication (2) and a US Pharmacopeial Convention (USP) stimuli article (3) and addresses:

- History and use of additives and processing aids in excipients
- Current regulatory position including acceptance of concomitant components as part of excipient composition
- Recommendations to ensure pharmaceutical products are not being deemed adulterated and/or misbranded.

This article focuses on the use of additives and processing aids in excipients with established safety profiles and precedence of use and the concerns with compliance to US Food and Drug Administration (FDA) labelling and USP General Notices requirements. The presence of additives, processing aids, and concomitant components has not been well understood by regulators and pharmaceutical manufacturers.

A follow up article will address concomitant components which, based on USP's stimuli article (3), are now recognized as a natural part of excipient composition and not as impurities. **Table I** provides the International Pharmaceutical Excipients Council (IPEC) definitions of common terms (4).

Excipient composition

Most excipients are not pure substances, but rather, multi-component ingredients that likely would not perform the same if any of the components were removed. Inherent residual and trace components present in excipients are important and can impact key excipient functional characteristics when used in pharmaceutical formulations. These components in excipients are not considered impurities by excipient manufacturers and could vary from supplier to supplier due to different raw materials and manufacturing processes. Although for APIs high purity is deemed a superior product, for excipients high purity is not necessarily better and may lead to decreased functional performance.

Examples of excipient components can be found in **Figure 1**.

George Collins is vice president, Vanderbilt Chemicals LLC. **Katherine Ulman** is president, KLU Consulting. **Douglas G. Muse** is consultant—Compndial Affairs, Eli Lilly & Co. **Elizabeth Tocce** is associate application development engineer, DuPont. **Chris Moreton** is principal, FinnBrit Associates. **Priscilla Zawislak** is global regulatory affairs advocacy manager, DuPont. **Joseph Zeleznik** is chair, IPEC-Americas QbD Committee. Direct inquiries to: ipecamer@ipecamerics.org.

Advances in analytical methodology and increased sensitivity have facilitated detection by pharmaceutical manufacturers of low levels of previously undetected components in well-established, widely used excipients. Unfortunately, this increased awareness has led to potential concerns that excipients and pharmaceutical products containing these excipients with previously undeclared additives, processing aids, and/or concomitant components could now be considered adulterated and/or misbranded. This is, in part, due to these new identified components being considered erroneously by some as impurities in excipients. In addition, compendial excipients having *United States Pharmacopeia–National Formulary (USP–NF)* monographs could face further issues because USP General Notices 5.20 (1) specifically prohibits the presence of such non-disclosed components.

Many additives, processing aids, and concomitant components have always been present and have had a long precedence of acceptable use in excipients. In addition, excipients containing these additives and processing aids have been safely used in pharmaceutical products for many years (sometimes decades) without incident. However, the identity of these additives and processing aids, as well as their presence, was often not disclosed in excipient composition profiles. In certain cases, excipient manufacturers have not been willing to disclose the identity of such components due to the proprietary nature of their use. As a result, there are a large number of excipients in approved medicines that contain undeclared additives, processing aids, and/or concomitant components.

There is typically a justifiable technical need for additive and processing aid inclusion in excipients. Additives and processing aids should not be reduced or eliminated, or considered as impurities, nor should excipients containing additives or processing aids be avoided without understanding the impact to pharmaceutical product safety or efficacy.

Additives and processing aids in excipients

Additives are important components commonly used at low concentrations in excipients. Additives provide certain functions such as enhancing stability, modifying pH, preventing microbial growth, etc. For many excipients currently containing additives, the absence of additives could adversely impact excipient performance and/or stability.

Processing aids are used by excipient manufacturers to support excipient manufacturing processes. Examples of processing aid functions might include reducing excipient adherence to manufacturing equipment, increasing powder flow through piping and hoppers/bins, and decreasing viscosity to facilitate pumping.


The benefits from process aid inclusion in excipient composition realized by excipient manufacturers might also be advantageous to pharmaceutical manufacturers. Often, the relationship between excipient composition, physical form, and performance is not fully understood. Removal of undeclared additives and/or residual processing aids could have unintended negative consequences, and the impact of the removal would have to be evaluated in all pharmaceutical products containing excipients with additives and/or processing aids. For example, switching from butylated hydroxytoluene (BHT) stabilized polyethylene glycol (PEG) to an additive-free PEG could compromise pharmaceutical product stability if the pharmaceutical product is unknowingly stabilized by the undeclared antioxidant contained in the excipient. Fully understanding excipient composition profiles, including potential undeclared additives or residual processing aids, via early dialog with excipient manufacturer, would avoid such problems. Additionally, having this information could help to avoid similar future problems should a new excipient and/or supplier be qualified where the substituted excipient comprises different additive or processing aid types or levels or is free of additives or processing aids altogether.

Table I: International Pharmaceutical Excipients Council (IPEC) definitions.

Term	Definition
Additive	A substance added to the excipient to improve or maintain a characteristic such as a preservative, flow agent, antimicrobial, etc.
Processing aid	Materials, excluding solvents, used to aid in the manufacture of an excipient, intermediate, or API that do not themselves participate in a chemical or biological reaction (e.g., filter aid, activated carbon, etc.).
Concomitant component	A substance found in an excipient that is not the intended chemical entity, may be necessary for assuring the proper performance of the excipient in its intended use, and is not an impurity or a foreign substance. (Formerly referred to as minor component, e.g., the main component in polysorbate 80 is oleic acid [~58%] and minor components include other fatty acids [~42%]).
Impurity	An undesirable material found in an excipient as a consequence of the raw materials, excipient manufacturing process, or excipient degradation.

Source: IPEC, "General Glossary of Terms and Acronyms" (Arlington, VA, 2014).

Figure 1: Examples of excipient components.



Many pharmaceutical excipients are also manufactured for non-pharmaceutical applications. These applications do not always require identification of additives and/or processing aids. Due to the multitude of industries that excipient manufacturers support, historically, they may not have understood how important it is for pharmaceutical manufacturers to know if additives and processing aids exist in their ingredients. In addition, intellectual property confidentiality concerns may be a factor in non-disclosure

of these components. As a result, unlike APIs, which are typically single entities, excipients are often complex substances that may contain components not appearing on labelling or in monographs. Differences in additives and/or processing aids due to raw material sourcing or manufacturing processes can result in different excipient composition profiles for seemingly identical excipients that meet the same pharmacopeial specifications. For pharmaceutical products, excipient substitutions

from one supplier to another supplier could have an adverse impact on product performance and could pose potential risks by compromising safety, stability, or efficacy.

Additives and processing aids can serve a variety of functions. These include, but are not limited to:

- **Anti-adherent agents.** Additives such as silica or talc may be used as anti-caking agents.
- **Antioxidants.** Antioxidants are agents that prevent the oxidation process, thus avoiding its deterioration. Potential antioxidants found in excipients might include ascorbic acid, butylated hydroxyanisole (BHA), and BHT.
- **Buffering agents.** Designed to control the pH drift. Examples of buffering agents might include sodium bicarbonate and calcium biphosphate.
- **Diluents/fillers.** Some excipients may contain diluents or fillers such as calcium carbonate and lactose.
- **Emulsifying agents.** Emulsifying agents might be added to an excipient (e.g., simethicone emulsion) to enhance the emulsion stability, thus avoiding separation between two phases. Examples include sodium lauryl sulfate and polysorbate 60.
- **Glidants.** Glidants may be added to powders or granules to enhance their flowability. Examples of glidants might include silica and/or silica derivatives.
- **Preservatives.** Preservatives may be added to excipients in order to prolong their shelf life by protecting them from micro-organism deterioration. Examples of preservatives might include benzoic acid and butylparaben.

Based on excipient good manufacturing practices (GMPs) (5), IPEC-Americas believes that additive and processing aid use should be controlled. The USP stimuli article (3) supports IPEC-Americas' position, as stated in their conclusion: "A distinction must be made between excipient impurities that detract from the quality of the excipient (including safety), and those components which can be present, have always been present, and which may need to be

present to achieve the necessary performance in the application."

Therefore, it should be clearly understood that additives and processing aids are not impurities.

The pharmaceutical industry is currently facing a dilemma where FDA and USP expect more detailed composition information in monographs and labelling.

Current regulatory situation

Due to excipient sourcing globalization and increased need to detect and prevent supply of adulterated ingredients, many new and modernized test methods are now finding previously undetected components in excipients. Historically, excipient manufacturers have used common techniques that measure single-variable characteristics, like solution pH, to confirm desired endpoints. These techniques do not detect the presence of multiple components of a product. With the concern for adulterated ingredients, more sophisticated methods, such as high-performance liquid chromatography (HPLC), are employed and can detect the presence of multiple components within a given sample. Although they are now being detected, these components have always been present but undetectable by older, less sophisticated methods.

Further, preclinical toxicology studies conducted on excipients containing additives and processing aids have not exposed any health or safety issues or any other adverse impact due to the presence of these excipient components.

FDA expects pharmaceutical manufacturers to have a thorough understanding of composition and impurities in pharmaceutical products. As a result, because these components had not been disclosed in the past, and because pharmaceutical manufacturers are analyzing for and finding these components due to advances in analytical techniques, it is not well understood if these components

have been added intentionally or in the case of concomitant components, are inherent to excipient composition and are not impurities.

IPEC-Americas survey. IPEC-Americas is concerned that discovery of additives or processing aids present in excipients could result in undue alarm and potentially trigger consequences that could negatively impact availability of pharmaceutical products when there is no safety concern. As a result, IPEC-Americas completed a survey to identify additives and/or processing aids that are integral to excipient composition. The survey identified a list of more than 70 additives currently undeclared in commonly used excipients with all but five of the additives currently listed as excipients in the FDA Inactive Ingredient Database (IID). Examples include, but are not limited to, silica, BHT, and propyl gallate.

Based on the survey results, IPEC-Americas developed a background document (6) that includes a list of additives and processing aids used in excipients, submitted a formal request to FDA in July 2017 (7) for a meeting to develop a strategy for handling undeclared additives and processing aids in excipients, and continues to look forward to dialoging with them.

Concerns with current USP policy. The excipient manufacturers have concerns about USP General Notices 5.60, which states, "the presence of an unlabelled other impurity in an official substance is a variance from the standard if the content is 0.1% or greater" (8). This is further complicated by USP General Notices 5.20 requirements that state, "Official substances may contain only the specific added substances that are permitted by the individual monograph. Such added substances shall not exceed the quantity required for providing their intended effect. Where such addition is permitted, the label shall indicate the name(s) and amount(s) of any added substance(s)" (1).

Therefore, based on USP General Notices 5.60 and 5.20, presence of undeclared additives or processing aids, at or above 0.1%, is not allowed.

This is a major concern to excipient manufacturers because undeclared additives or processing aids are present in many USP- or NF-grade excipients currently used in pharmaceutical products and typically this has been the case for many years.

Ensuring drugs are not being deemed adulterated and/or misbranded

The pharmaceutical industry is currently facing a dilemma where FDA and USP expect more detailed composition information in monographs and labelling. In addition, pharmaceutical manufacturers need a better understanding of excipient composition. However, excipient manufacturers may need to keep certain additive and processing aid information confidential for intellectual property or trade secret reasons. Resolving this issue will require collaboration by all impacted stakeholders.

Historically, there has not been a consistent approach to disclosure of additives and processing aids in excipients, even though they have been used for many years without adversely impacting product safety. Given the large number of excipients currently in approved medicines containing undeclared additives or processing aids, and the much greater number of pharmaceutical products potentially affected, there is an urgent need for the pharmaceutical and excipient industries, FDA, and USP to collaborate in developing a strategy for addressing additives and processing aids in excipients. This approach should allow excipient suppliers to share confidential information with FDA without direct disclosure of the identity and level of additives and/or processing aids to pharmaceutical manufacturers.

Specific recommendations from IPEC–Americas include:

1. To avoid restricting current, safe excipient use, FDA should review and acknowledge additives and processing aids not listed in the IID, but which have historically been present in and demonstrated to be safely used in excipients.
2. FDA should exercise enforcement discretion to allow additives and processing aids, listed in the IID and present in excipients, as well as individually in pharmaceutical product formulations to exceed IID maximum potency limits in final pharmaceutical products, if it can be shown that there is a precedence of use in excipients having been used in the route of administration being reviewed.
3. FDA, USP, and industry stakeholders should collaborate to develop a strategy that addresses how intellectual property and labelling issues related to additives and processing aids might be handled. One such approach could include a bridging justification, reference to use in food, or generally recognized as safe (GRAS) position to justify the safety.
4. USP should include identified excipient additives and processing aids in the exclusion list for compliance with USP General Notices 5.60.10 impurity labelling requirements. Current list of exclusions includes:
 - Fermentation products and semi-synthetics derived therefrom
 - Radiopharmaceuticals
 - Biologics
 - Biotechnology-derived products
 - Peptides
 - Herbals
 - Crude products of animal or plant origin.

TAKING A PILL IS AS EASY AS PIE? 50% OF YOUR CUSTOMERS WOULD DISAGREE ...



Visit us at CPhI 2019 in Frankfurt, stand 120D81

A recent study proves that more than half of the population has problems swallowing tablets and capsules. From breaking and dissolving to not taking them at all, people invent their own strategies to cope with tablets – which may reduce efficacy and treatment success.

We at HERMES PHARMA have over 40 years of experience in making medicines easier to take – from product design through to manufacturing and packaging.



Scan QR-code or visit
www.swallowingtablets.com
to get a free copy of the market study.

**HERMES
PHARMA**

Get the dose right®

5. USP should create a new General Notice section 5.20.15 that exempts excipients from declaring specific additive and processing aid types and levels on labelling unless the excipient manufacturer desires to do so. This information, when considered confidential by the excipient manufacturer, can be shared with FDA using a Type IV drug master file (DMF) and referenced in drug applications using a letter of authorization. The excipient manufacturer, however, would need to identify that an additive or processing aid was present.

Conclusion

Many excipients contain additives and/or processing aids to enhance performance or facilitate manufacture. While additives can be used for such purposes as pH buffering, controlling microbial contamination, preservation, etc., processing aids are used to improve manufacturing processing and efficiency. Many additives and processing aids contained in excipients may not be found on labelling or in monographs, and additive and processing aid concentrations and types may differ among excipient manufacturers. Generally, additives and processing aids are themselves excipients or food additives and have been used safely in pharmaceutical products for years and sometimes decades. As a result, their presence in pharmaceutical products poses no risk to patient safety. However, while additive and processing aid use pose no safety risk, absence of these components could compromise pharmaceutical product stability and efficacy.

USP General Notices 5.20 and 5.60, in their current language, require additives and processing aids to be on labels and reported when used at levels >0.1% (based on International Council for Harmonization Q3B). Such a requirement(s) may present challenges for excipient manufacturers due to confidentiality concerns and for pharmaceutical manufacturers who may not

understand the complete excipient composition profile. IPEC-Americas recommends changes to USP General Notices 5.20 and 5.60 regarding labelling requirements for additives and processing aids.

IPEC-Americas takes the position that excipient and pharmaceutical manufacturers should have open communication regarding the potential for the presence of additives and processing aids (9–11). This can include use of confidentiality disclosure agreements during excipient/supplier qualification. Details for accessing information regarding additive and processing aid use also may be via DMF, when appropriate. However, in other regions (e.g., Europe) where excipient DMFs are not applicable, the need for further discussion with regulators may be required.

Lastly, stakeholders, USP, and FDA, need to collaborate and develop a path forward that would affect the following:

- Ensure that identification of low levels of additives and processing aids in established excipients does not lead to pharmaceutical products being deemed adulterated and/or misbranded.
- Ensure that excipients containing additives and/or processing aids comply with revised USP requirements (as proposed).
- Create a means to share the above information in a manner

that does not compromise excipient manufacturer's intellectual property.

References

1. USP, *USP 40-NF 35* [Official May 1, 2017], p. 5.20.10 (USP, Rockville, MD, 2015).
2. Carlin et. al, *Pharm Tech* 41 (10) 54-63 (October 2017).
3. USP, "The Complexity of Setting Compendial Specifications for Excipient Composition and Impurities," *USP Pharmaceutical Forum* 44 (3) 1 May 2018
4. IPEC, "General Glossary of Terms and Acronyms," (Arlington, VA, 2014).
5. NSF/IPEC/ANSI 363–2016 Good Manufacturing Practices (GMP) for Pharmaceutical Excipients.
6. IPEC-Americas backgrounder document for "Additives in Pharmaceutical Excipients."
7. IPEC-Americas letter to Dr. Lawrence Yu, Deputy Director OPQ, FDA, July 25, 2017.
8. USP, *USP 40-NF 35* [Official 1 May 2017], p. 5.60.10 (USP, Rockville, MD, 2015).
9. IPEC, *The IPEC Excipient Composition Guide* (2009).
10. J. Zeleznik and G. Collins, "Additives & Concomitant Components vs Impurities in Pharmaceutical Excipients," IPEC-Americas Webinar, March 2018.
11. B. Carlin and R.C. Moreton, "The Importance of Excipient Composition and Complexity," IPEC-Americas Webinar, November 2018. [PTE](#)

More on excipients

For more on excipients, go to www.PharmTech.com to read the following:

- Avoiding Excipient Variability
www.PharmTech.com/excipients-2
- Strategic Screening for Solubility Solutions
www.PharmTech.com/strategic-screening-solubility-solutions
- How Third-Party Audits Can Help Ensure Excipient Quality
www.PharmTech.com/how-third-party-audits-can-help-ensure-excipient-quality
- Paving the Way for Modernized Drug-Product Manufacturing Through Excipients
www.PharmTech.com/paving-way-modernized-drug-product-manufacturing-through-excipients
- Selecting Excipients for Liquid-Filled Hard Capsules
www.PharmTech.com/selecting-excipients-liquid-filled-hard-capsules

Regulating Excipient Quality, No Mean Feat

Regulatory bodies are taking a more stringent approach to excipient quality, but unlike guidance on GMP for APIs, those for excipients offer a framework only, meaning the onus lies with the manufacturer or supplier.



Felicity Thomas

In recent years, regulatory bodies across the globe have been taking a more stringent approach to excipient quality. Within the European Union (EU) alone, regulatory guidance on the assessment of risk related to excipients was published in 2015 and required to be implemented by 2016 (1). However, these guidelines only offer a general framework from which pharmaceutical companies and excipient suppliers can look to develop their own appropriate ways of ensuring excipient quality.

To learn more about the European regulatory guidance, its implementation, potential impact on workloads, and best practices for companies and excipient suppliers, *Pharmaceutical Technology Europe* spoke with Frithjof Holtz, advocacy and surveillance—life science regulatory management, Merck KGaA.

Regulating excipients

PTE: Could you elaborate on the EU regulations surrounding excipients and how these have developed over the years?

Holtz (Merck): The critical role of excipients in drug production has come into focus over the past few years. This has meant shaking off the long prevailing perception of excipients being passive additions to APIs. Now, regulatory authorities are calling for more stringent quality management in excipient production and use, leading to new requirements for both excipient suppliers and pharmaceutical manufacturers.

Regulating excipient quality, however, is no small task. More than 1000 different excipients are available, and only a small fraction is manufactured solely for pharmaceutical use. This heterogeneity and the resulting complexity have led to the European Commission's (EC's) approach to excipient quality.

In 2011, the EU's Falsified Medicines Directive established that pharmaceutical manufacturers must perform a formalized risk assessment for each excipient they use and determine its appropriate good manufacturing practices (GMPs). It also

stated that the EC would develop guidelines offering direction on the risk management process and the appropriate level of GMP for excipients. Based on this directive, the EU excipient risk assessment guidelines were drafted in 2013 and published in March 2015 after intense discussion.

The guidelines apply not only to medicinal products produced in Europe but also for products manufactured outside Europe and intended for the European market. Since 21 March 2016, excipient users in the EU are legally mandated to implement GMP requirements, including comprehensive risk assessments for each excipient.

The EU excipient risk assessment guidelines capture both the intended use and source of the excipients. Its main topics are described in chapter two to four, covering the determination of appropriate GMP based on type and use of excipient, the determination of an excipient manufacturer's risk profile, as well as confirmation of application of appropriate GMP.

However, while regulations regarding GMP for APIs clearly define what is needed for compliance, the EU excipient risk assessment guidelines are—as the name suggests—not more than guidelines that offer tools and a framework but do not prescribe how to implement them. They neither provide detailed instructions nor a clear definition of appropriate GMP for excipients. This is the responsibility of the manufacturing authorization holder—and, evidently, no small task either.

PTE: Why has the EC taken a risk-based approach to excipient quality?

Holtz (Merck): A risk-based approach is the most logical way of assessing excipient quality. Some excipients pose much greater risks than others. Risks vary depending on the route of administration and the function of the excipient. An excipient used as filler, for instance a binder or colourant, might pose a lower risk than one

used as a stabilizer or a vehicle for controlled release. Hence, the risk-based approach focuses on the harm posed by microbiological, chemical, or physical hazards.

Due to the risk excipients can pose to patients, robust excipient GMPs are needed. Increased attention to supply chains and more structured communication between excipient suppliers and drug manufacturers are essential in order to help reduce risks. Drug manufacturers should expect their suppliers to provide dossiers accompanying each excipient with information that, in turn, supports the drug manufacturer's risk assessment. This can include data on production, testing, supply chain and quality systems, as well as information about alignment with regulatory guidelines.

Implications and potential aides for manufacturers

PTE: Are there significant workload implications for manufacturing authorization holders, and are there any solutions available to ease the workload?

Holtz (Merck): It is important to understand that the EU excipient risk assessment guidelines offer a general framework. Developing a compliant risk assessment process and defining appropriate GMPs for all excipients is clearly the responsibility of the medicinal product manufacturer. However, there is no need for manufacturers and users of excipients to develop their own GMPs. Several well-established, voluntary industry standards can be used for guidance, such as the International Pharmaceutical Excipients Council-Pharmaceutical Quality Group (IPEC-PQG) GMP Guide, *United States Pharmacopeia (USP) General Chapter <1078>*, EXCiPACT, and NSF/IPEC/ANSI-363-2016.

Take the IPEC-PQG GMP Guide as an example, it provides an in-depth description of a voluntary GMP guide for pharmaceutical excipients. Together with the IPEC Europe 'how-to' document on *EU Guidelines on Risk Assessment for Excipients* published in 2016,

it gives a good initial guidance (2). The step-by-step document also offers a clearly arranged process overview of how to comply with the requirements outlined in the EU excipient risk assessment guidelines. In many cases, application of these standards is likely to be sufficient. However, a small number of excipients could potentially pose hazards to patients and require application of more thorough controls than those recommended in the voluntary standards.

"Drug manufacturers should expect their suppliers to provide dossiers accompanying each excipient with information that, in turn, supports the drug manufacturer's risk assessment."

—Holtz (Merck)

Unfortunately, manufacturers and users of excipients are often still at a loss as to how exactly they should perform their risk assessment. Given the abundance of excipients, a formalized risk assessment might even seem unmanageable. Also, the sheer number of supporting documents can be overwhelming, as helpful as they might be. So yes, the more stringent regulations have increased the workload of all parties involved. Performing excipient risk assessment in a structured manner requires a lot of effort and has significantly changed the daily work of excipient users and manufacturers.

Although the voluntary industry standards are a great help, they are not binding, but based on best industry practices, offering guidance and facilitating implementation. As described before, excipient suppliers and pharmaceutical manufacturers are still facing the complicated task of putting these standards into practice.

As a result of these complexities, Merck has developed the

Improve programme (3). The intention of the programme is to simplify processes and to help drug manufacturers master the challenges of timely information, structured communication, and 'inspection-friendly' documentation. Dossiers, which are available 24/7 online and backed by comprehensive support, cover the relevant EU guidelines, with constant reference to the respective chapters. Additional information, such as a quality self-assessment and detailed supply information, is also included in the dossiers. Regarding excipient risk assessment, the tools and information help to efficiently implement a compliant and sustainable risk assessment process, which makes pharmaceutical manufacturers optimally prepared for inspections.

Best practices

PTE: Do you have any best practices for companies to successfully prepare for excipient risk assessment inspections?

Holtz (Merck): Absolutely, a few months ago, we [at Merck] conducted a real-life case study to simplify the task and to enable effective learning through practical experience. We began by selecting medicinal products to identify all relevant excipients and their respective use. This selection resulted in a total of 24 excipients for inclusion in our investigation and assessment.

Based on the EU guideline, we then compiled criteria for manufacturing and supply, as well as application. This led to the definition of five different quality areas: quality management system (QMS), manufacturing of excipients, supply chain, route of administration, and function of the excipient. Based on these initial considerations, we conducted the case study in four distinct steps.

The first step focused on supplier qualification. The EU guidelines were translated into a supplier questionnaire. The incoming information was harmonized and bundled in a spreadsheet.

Next, we developed an excipient risk ranking template covering all elements of the EU guidelines. It provides a risk score (low, medium, and high) for each individual excipient for each criterion as well as the overall risk score. As recommended by the EU guidelines, we used International Council for Harmonization (ICH) Q9 Quality Risk Management as guidance for risk prioritization (4).

Finding an appropriate procedure for risk prioritization of the responses was by far the greatest challenge. Here, suppliers can actively contribute to a good risk assessment process by following established guidelines, fulfilling information needs and providing timely documentation, ideally bundled in packages and transmitted electronically.

Step three determined the supplier risk, based on the previous definition of minimum requirements derived from the IPEC-PQG GMP Guide and EXCiPACT.

Finally, a risk profile for each supplier was created based on a gap analysis. The goal was to find effective mitigation options, such as an update of the quality assurance agreement or intensified incoming goods control.

All 24 excipients were classified as medium risk. It is important to note that this classification represents an overall ranking, as explicitly required by the guidelines. This means that excipients might show high single risks—which need to be closely looked into—but are still classified as medium risk overall. The high single risks showed that storage monitoring and packaging are important considerations regarding the excipient's source, whereas dosage form, permanent intake, and function are predominant regarding the excipients' use.

The gap analysis at the supplier end resulted in 14 excipients classified as low, and 10 as medium risk. The identified gaps include a potential for microbiological or endotoxin/pyrogen contamination—with

the mitigation option to perform additional quality control testing in the manufacturing authorization holder's laboratory. Other identified gaps concerned environmental control and control of storage/transportation conditions including cold chain management and packaging integrity.

“It is important to note that the risk assessment cannot replace regular audits, since the information provided by suppliers and manufacturers does not necessarily reflect the degree of compliance in daily work.”

—Holtz (Merck)

One of the main challenges we recognized in conducting our analysis was in obtaining meaningful data. Supplier data input to our survey was sometimes incomplete, contradictory, not as requested or not delivered in a unified format. Also, data transfer and dealing with large spreadsheets was an error-prone and time-consuming task. More clearly defined instructions for suppliers might be able to solve this challenge.

Another major challenge we encountered is providing a sustainable risk assessment process that can be easily incorporated into daily business to keep it up to date. However, it is important to note that the risk assessment cannot replace regular audits, since the information provided by suppliers and manufacturers does not necessarily reflect the degree of compliance in daily work.

Future predictions

PTE: What do you believe the excipient suppliers and pharma manufacturers should anticipate in terms of regulatory guidance and required compliance for quality of excipients in the near future?

Holtz (Merck): I see two important areas. The first is multicompendial compliance. Unfortunately, pharmacopoeial harmonization has not led to the expected results. Manufacturers and users of excipients still need to cross-validate pharmacopoeial standards, as long as the industry is lacking a standardized approach. The industry needs to develop a best practice that is accepted by regulatory authorities. This would enable companies to align their internal procedures for compliance with multiple compendia.

Second, novel excipients are prevented from being introduced in the EU due to the absence of an excipient master file system. Major regulatory environments such as Japan, US, Canada, and China, have design master file-type systems in place and treat novel excipients as APIs, requiring comprehensive manufacturing, quality, and safety data. In Europe, however, there is no way to directly submit confidential information for an excipient in a centrally authorized product. A regulatory pathway that guarantees the protection of confidential manufacturing know-how for novel excipients would encourage innovation.

References

1. EU, “Guidelines of 19 March 2015 on the Formalized Risk Assessment for Ascertaining the Appropriate Good Manufacturing Practice for Excipients of Medicinal Products for Human Use,” *Official Journal of the European Union*, 58 10–13 (2015).
2. IPEC Europe, “‘How-To’ Document: Guidelines of 19 March 2015 on the Formalized Risk Assessment for Ascertaining the Appropriate Good Manufacturing Practice for Excipients of Medicinal Products for Human Use (OJ 2015/C 95/02),” *Guide, gmp, compliance.org* (Brussels, 2016).
3. Merck, “The Emprove Program,” Regulatory Support Information, *merckmillipore.com* [Accessed 19 August 2019].
4. ICH, *Q9 Quality Risk Management* (ICH, 9 November 2005). **PTE**

How Excipient Type Influences Self-Emulsifying Drug Delivery

High-throughput platforms can be used to develop tertiary phase diagrams, which can be leveraged to identify the most stable SEDDS formulations for lipid-based drug delivery systems.

Frank Romanski, PhD is head of Global Marketing, Pharma Solutions, BASF Corp, Florham Park, NJ, frank.romanski@basf.com.

Most published estimates state that greater than 70% of drugs in the small-molecule pipelines are considered poorly water soluble. Because the human body requires that a drug essentially be solubilized in an aqueous environment, this poor water solubility poses an enormous challenge to effective drug delivery. Drugs may be poorly water soluble for a number of reasons, such as molecules with strong crystal lattices and high melting points or, on the other end of the spectrum, drugs exhibiting extremely high hydrophobicity that simply do not interact physico-chemically with water. If these drugs are not solubilized, they cannot be absorbed and are thus not producing a therapeutic effect. As the “easy” molecules (i.e., both water soluble and readily absorbed) become more rare in modern pharmaceutical pipelines, effective technological and formulation strategies need to be developed to effectively deliver the poorly water soluble molecules (i.e., APIs in BCS Class II and IV).

One key aspect for these formulations and technologies is that they need to be practical; formulations must be straightforward to manufacture, as well as pragmatic for the patient to consume. Thus, techniques such as amorphous solid dispersions (ASDs), which are made using hot melt extrusion and spray drying, and lipid-based drug delivery systems (LBDDS) are effectively used in the majority of the poorly water-soluble drugs brought to market. ASDs can be easily formulated into tablets, which are a widely accepted dosage form to be manufactured and ultimately consumed. LBDDS, with formulations that are often liquid or semi-solid, may be produced into hard or softgel capsules, which are also highly accepted from a patient compliance standpoint, and the knowledge base to manufacture these and scale them up exists within the industry. Despite the ease of manufacturing, however, the challenge remains of how to properly formulate LBDDS, and more specifically, self-emulsifying drug delivery systems (SEDDS), which are notoriously difficult to formulate from scratch.

LBDDS delivery mechanism

LBDDS use the body's own mechanisms to effectively deliver drugs. As an example, when the body digests a fatty meal, the lipids and fats are dispersed through the gastrointestinal tract (GIT), where they are emulsified and subsequently absorbed. During the digestion process, lipophilic solubilized vitamins and nutrients are absorbed. LBDDS and more specifically, SEDDS, work using this same mechanism. The encapsulated formulation releases from the capsule in the stomach or intestine (which may be targeted through enteric or sustained release coatings); the oils are emulsified and stabilized by the surfactant phase to form small droplets, which consequently allow for rapid absorption of the drug into the body. Once dispersed, these are effectively an oil/water (O/W) emulsion. One could start with a predispersed O/W emulsion; however, a formulator cannot encapsulate an O/W emulsion effectively because it is inherently unstable from a thermodynamic perspective, and over a relatively short amount of time it will fully separate. To overcome this tendency and to formulate a truly stable system requires creating a microemulsion, which no longer has a defined oil and water phase, but rather a bicontinuous phase. Unlike traditional O/W or water/oil (W/O) emulsions, these are thermodynamically stable, clear, low viscosity, and exhibit a high capacity for drug solubilization. The stable region is drawn theoretically in **Figure 1**.




Microemulsion regions are also drawn using the classic fishtail diagram (see **Figure 2**), where the Winsor Type IV emulsions have the right blend of oil, water, and surfactant to maintain an equilibrium bicontinuous system. In these systems, there are no true droplets, but rather single digit nanoscale structures that coexist. The Y-axis on the diagram in **Figure 2** may be the surfactant blend (hydrophilic surfactant and hydrophobic surfactant) or the temperature of the system.

It is these Winsor Type IV microemulsions that may be encapsulated effectively. Once



Coating Place

Original Wurster Technology



Oradel[®]
Oral Delivery Innovation

At Coating Place, every coating formulation is customized based on the unique characteristics of the project. Using our **Oradel[®]** oral delivery techniques, we can achieve a wide variety of release profiles. With over 40 years of experience in the CDMO industry, Coating Place offers technologically advanced Wurster fluid bed coating, high quality coating, linear scalability and superior customer service.

Innovative Development. Experienced Manufacturing.

Coating Place, Inc., 200 Paoli St. • PO Box 930310, Verona, Wisconsin 53593 U.S.A.
+1 (608) 845-9521 • www.coatingplace.com • info@coatingplace.com

Figure 1: Microemulsions exhibit a stable region.




Figure 2: A fishtail diagram shows microemulsion regions; O is oil; W is water; S is surfactant.





Figure 3: The stable regime is indicated by the green dots in the tertiary (oil, water, surfactant phase) diagram. The oil phase is a medium chain triglyceride (Kollisolv MCT 70, BASF).



these stable microemulsion systems inside of the capsules meet with the aqueous environment of the GIT, the system shifts to an O/W emulsion. Depending on the formulation, droplets can range from tens of nanometers to millimeters in diameter. These droplets encapsulate the poorly water-soluble drug and allow for absorption of the API as the oil is digested, forming micelles and other complex colloidal structures. In theory, this approach works well, but in reality, it can be challenging to isolate stable microemulsion regions within a given system in order to build formulations.

Formulating stable systems

SEDDS, which create tiny nano-scale droplets upon contact with the GIT, are highly effective, and a number of APIs have been recently approved that use this formulation approach (e.g., Rydapt, Neoral, Avodart, Norvir). However, what is yet to be comprehensively studied is the effect of excipients on the formulations. Although it is generally accepted that an oil-phase, primary surfactant, and secondary surfactant are required to effectively formulate these products, scientists must often work with existing formulations. Otherwise, they must start from scratch, which can require hundreds if not thousands of experiments.

With the aim of reducing the amount of experimentation and the time required to evaluate the applicability of SEDDS for different formulations, the author and his colleagues developed an approach that may be useful in future work. Their research, summarized in this article, used a high-throughput robotic system to establish tertiary phase diagrams (Figure 3) to determine stable regimes within these surfactant, oil, and water phase diagrams. Then different formulations using different surfactants, oils and aqueous phases were evaluated within this stable range to determine their applicability.

Within the stable region indicated by the green dots in Figure 3, a series of formulations were crafted to comprehensively study the effect of excipients on the formulations by varying the oil phase, aqueous

Table I. Stable formulations (F1 to F10) for self-emulsifying drug delivery were designed to aid formulation of lipid-based drug delivery systems for poorly water soluble APIs.

	Medium chain triglyceride (Kollisolv MCT 70, BASF) (%) (w/w)	Soybean oil (%) (w/w)	Maisine 35-1 (%) (w/w)	Corn oil (%) (w/w)	Glycerol monocaprylo-caprate (%) (w/w)	Polyoxyl 40 hydrogenated castor oil (Kolliphor RH40, BASF) (%) (w/w)	Poloxamer 124 (Kollisolv P124, BASF) (%) (w/w)	Polyoxyl 35 castor oil (Kolliphor EL, BASF) (%) (w/w)	Glyceryl Monooleate (%) (w/w)	Water (%) (w/w)	Ethanol (%) (w/w)
F1	-	27.5	27.5	-	-	35	-	-	-	-	10
F2	10	-	-	-	-	68	-	-	12	10	-
F3	40	-	-	-	-	42.5	-	-	7.5	10	-
F4	10	-	-	-	-	-	-	68	12	10	-
F5	40	-	-	-	-	-	-	42.5	7.5	10	-
F6	10	-	-	-	-	-	68	-	12	-	10
F7	-	10	-	-	-	68	-	-	12	10	-
F8	-	-	-	10	-	68	-	-	12	10	-
F9	10	-	-	-	12	68	-	-	-	10	-
F10	40	-	-	-	7.5	42.5	-	-	-	10	-

phase, and surfactant/blend phase. An aqueous phase was studied because, in most encapsulations (particularly with softgels), moisture ultimately enters the system and reaches an equilibrium with the non-ionic surfactants, sometimes at concentrations greater than 5% w/w. The approach of formulating with an aqueous phase of 10% (either as water, ethanol, or others) builds robustness into the formulation and enhances the ability to maintain stability in the future. This phase may be either water or ethanol; ethanol allows for higher levels of drug solubility and better miscibility between the phases but may pose additional formulation challenges, such as the handling of flammable solvents during manufacturing.

Next, the oil phase, which is primarily responsible for solubilization of the drug and is the primary ingredient that is digested, was designed to be varied based on the solubility of the drug, rate of digestion (e.g., medium chain triglycerides digest faster than long chain), and the concentration, which further affects the digestion rate.

Finally, the surfactant phase was designed. This phase is primarily responsible for the stability of the system as a microemulsion as well as the size and stability of the droplets after the microemulsion “breaks” to form an O/W emulsion. Typically, and in the case of these examples,

one would use a hydrophilic and a hydrophobic surfactant to balance the phases and enable the formation of a true microemulsion; this case was also tested by high-throughput screening. The results of these efforts were 10 stable formulations that can be used at multiple temperatures, aqueous/moisture levels, and different applications, as shown in **Table I**.

Formulation test results

Formulations were tested using model drug compounds and studied for stability, robustness, dispersibility, and digestibility using *in vitro* models (1). These were further corroborated by observing *in vivo* absorption using a rat model.

Each of the formulations listed in **Table I** exhibits unique properties. The use of ethanol, in the case of F1 and F6, allows for higher drug solubility and rapid dispersibility in aqueous media. Those using potent concentrations of surfactant, such as a non-ionic oil-in-water solubilizer and emulsifying agent (Kolliphor RH 40, BASF) used in formulas F2 and F3, exhibit very small droplet sizes upon release (10s of nanometers) and highly stable micellar systems once the oil is digested, although it is important to note that they generally require a few minutes to fully disperse from the capsules. Similarly, those made with a non-ionic oil-in-water emulsifier and

solubilizer (Kolliphor EL, BASF) used in formulas F4 and F5, exhibit small droplet dispersions, but a slightly faster digestion due to the faster digestibility of the surfactant. Formula F6 uses a liquid poloxamer surfactant (Kollisolv P124, BASF), which allows for rapid dispersion, but sacrifices stability of the oil droplets. By using other oils, such as soybean and corn oil (formulas F7 and F8, respectively), digestion rates may be varied (MCT being the fastest typically, soybean the slowest), and the solubility of the API may be tailored. Finally, co-surfactants, while a minor component, are key to maintaining the microemulsion. Several formulations are shown using glyceryl monooleate (formulas F2, F3, F4, F5, F6, F7, F8) and glyceryl monocaprylocaprate (formulas F9 and F10), offering different droplet sizes and digestion rates.

Best practices for testing formulations with an API

In order to test one of these formulations, it is generally recommended that the API be first saturated into the oil phase, which can be done by stirring overnight and filtering and testing API content by ultraviolet (UV) spectroscopy or high-performance liquid chromatography. Oil phases (oil + hydrophobic surfactant) and water phases (aqueous + hydrophilic surfactant) should be heated to approximately

Figure 5: Digestion over 90 minutes with formulation F2 (left) and F3 (right). The orange line is the titrated free fatty acid (digestion rate); the grey bar is solubilized and available API; and the black bar is precipitated, unavailable API.





Figure 4: Digestion rates of the formulations (F1 to F10).



60 °C and lightly mixed by hand; the microemulsions self-assemble. The resulting microemulsion may then cool and be dispensed into soft- or hard-shell capsules. Generally, the oil phase will be preloaded with API for formulation. It is recommended that approximately 80% of saturation in the total formulation be used for the final formulation to maintain API stability.

Testing of these formulations can be challenging, because in a standard dissolution bath with UV filter it is often too difficult to parse the API concentration from the droplets, micelles, and other phases in the bath. Therefore, it is recommended that formulators test these using lipolysis, membrane-based absorption models (macroFlux, Pion) or cell-based methods, such as Caco-2. Using a lipolysis mode and

the model drug Danazol (synthetic steroid, MP 224.2°C, 337.46 g/mol, LogP = 3.62), the varied digestion rates of the 10 formulations can be clearly noted, as shown in **Figure 4**.

Those formulations with a higher oil content, particularly those with medium chain triglycerides (Kollisolv MCT 70, BASF) exhibit the fastest digestion over one hour in intestinal media. Comparing the digestibility as well as the solubility of the API, one can compare formulations more succinctly. As an example, formulation F2, with high concentrations of Polyoxyl 40 hydrogenated castor oil (Kolliphor RH 40, BASF), disperses into nanoscale droplets and is digested slowly. Formulation F3, with the same ingredients but a much higher oil concentration, exhibits a much faster digestion rate and higher API capacity but sacrifices the size of the resulting oil droplets. Over a 90-minute digestion, these differences can be seen as graphed in **Figure 5**: the orange line is the titrated free fatty acid (digestion rate); the grey is solubilized and available API; and the black, precipitated unavailable API.

In summary, the formation of microemulsions is a challenge that can be overcome using modern methods such as robotic high throughput screening. These identified regions can then be utilized to craft functional pharmaceutical formulations capable of varied API loading, digestion rates, and dispersibility. The ten new formulations described in **Table 1** are available for formulators to place “on the shelf” as more challenging APIs come through the pipeline.

Reference

1. S.D.S Jorgensen, et. al. *Eur. J. Pharmaceutics and Biopharmaceutics* 124, 116-124 (2018). **PTe**

More on formulation

For more on formulating poorly water-soluble molecules, go to www.PharmTech.com to read the following:

- Developing Lipid-Based Formulations
www.PharmTech.com/developing-lipid-based-formulations
- Selecting a Solid Approach
www.PharmTech.com/selecting-solid-approach
- Enabling Technologies Advance Poorly Soluble Highly Potent APIs
www.PharmTech.com/enabling-technologies-advance-poorly-soluble-highly-potent-apis
- Selecting Excipients for Liquid-Filled Hard Capsules
www.PharmTech.com/selecting-excipients-liquid-filled-hard-capsules



Annex 1 Considerations for Fill/Finish

Equipment and systems for aseptic transfer and manufacture meet cGMP requirements.

Jürgen Metzger

is Barrier Systems & Process Specialist at Robert Bosch Packaging Technology, Inc., Juergen.Metzger@bosch.com.

On 20 December 2017, the European Commission published the long-awaited revision draft of *EudraLex, Volume 4, EU Guidelines to Good Manufacturing Practice Medicinal Products for Human and Veterinary Use, Annex 1, Manufacture of Sterile Medicinal Products* (1). Even before its release, Annex 1 has triggered many heated debates on how it will influence existing aseptic manufacturing processes, and these debates have further intensified after publication. On the one hand, some paragraphs leave a lot of room for interpretation. On the other hand, the industry fears overregulation.

Some of the most frequently discussed topics of Annex 1 include material classification for sterile transfers, more detailed risk assessment procedures for processes and the associated environment, more operational qualification (OQ) testing, and laminar flow (LF) conditions for loading and preparing machines for production as well as reducing the overall risk from human intervention. These topics lead to the question how to evaluate and justify the use of a certain solution and how to increase sterility with available equipment.

Most importantly, the revision draft aims to achieve an industry-wide agreement on a high level of standards, while keeping costs and efforts under control. Major scientific advances are leading to pioneering developments and changes in the bio/pharma industry. In parallel, manufacturing processes are changing at a rapid pace, with the goals of making processes safer, monitoring them more closely, and making overall production more transparent. Achieving these goals includes minimizing contamination, instructing staff in the best possible way, and continuously securing quality in all areas. Advanced equipment and manufacturing systems are also helpful in achieving these goals. This article reviews some of the technologies and trends in equipment and systems that can be considered for GMP aseptic manufacturing.

Automation

Supported by the revision of Annex 1, an increasing demand for automation and robotic systems, such as the equipment shown in

Figure 1, can already be observed throughout the industry. A reduction of gloves and human interventions to the absolute minimum in barrier systems in the future and ideally “gloveless” systems wherever possible can be expected. Restricted access barrier systems (RABS) are bound to undergo the most fundamental changes through integration of more robust and reproducible procedures for material transfer, as well as cleaning and biodecontamination. Most importantly, the use of robotics will further reduce risk factors such as human intervention or particles, and thus contribute to maintaining grade A conditions throughout the process. Abrasion-resistant materials and processes (e.g., levitating transport systems) and robotic transfer solutions are already revolutionizing aseptic processing.

At the same time, so-called Industry 4.0 (i.e., “connected industry”) solutions based on new software developments will change the pharmaceutical production landscape. Older equipment can be retrofitted, and new solutions are already available that closely monitor all processes and facilitate maintenance with preventive (and in the future even predictive) models, which significantly reduces the level of unforeseen interventions.

RABS and isolators

Choosing RABS or isolator technology is a strategic decision. All types of RABS are operated in ISO 7 (EU cGMP Grade B), while isolators and containment systems are operated in ISO 8 (EU cGMP Grade C [D]). The transfer of goods to RABS is generally handled under laminar-flow (LF) conditions and is still often performed manually. Isolator and containment systems, however, use a fast hydrogen peroxide transfer chamber, as well as integrated and more automated rapid transfer ports (RTP), for instance for the supply of stoppers and caps. The main difference between RABS and isolators is the decontamination cycle in a closed, well-monitored isolator, which increases sterility assurance on top of general cleaning procedures. Figure 2 shows an example of an isolator for fill/finish.

Figure 1: Robotics, such as the Bosch robotic filler handling unit, reduces the risks associated with particles and human intervention.



Figure 2: Isolators such as this one from Bosch Packaging Technology are used globally at pharmaceutical manufacturing sites.



RABS, however, are increasingly being treated as isolators. RABS are operated with locked doors during the entire production and feature robotic process steps and product transfer. RABS now often have RTPs just like isolators, as well as sophisticated airlocks with active (Grade A) LF supply. Whether isolators or RABS are used, the most important goal of Annex 1 is to achieve the highest quality by reducing contamination through microorganisms, particles, or pyrogens to a minimum and, subsequently, to reduce human intervention as much as possible.

Single-use filling systems

But even without human intervention, a certain risk for contamination remains. Industry insiders often discuss the “ring of concern”—the fact that every aseptic transfer system has a weak point. Many technical solutions try to optimize and monitor this point, for example, by using fully automated sterilizable transfer ports and valves. There are many ways of bringing products and materials into barrier systems.

A general distinction can be made between continuous (e.g., mouse hole, e-beam, hot air tunnel) and discontinuous transfer systems (e.g., RTP, airlocks, or liquid transfer systems during campaigns).

When transferring aseptic liquids between two areas with different containment classifications, for example, the classical solution of hard pipes with clean-in-place/sterilize-in-place (CIP/SIP) systems is still common. Whereas, single-use liquid filling systems are becoming more and more popular and are replacing the hard pipe solutions wherever possible. These systems are often favoured for their practical simplicity.

Single-use liquid filling equipment (e.g., connectors, needles, tubing, or intermediate bags) comes presterilized, preassembled, and prevalidated in multiple wrapped bags, enabling their use for either traditional vessels or fully disposable fluid handling technologies, such as the single-use systems shown in **Figure 3**. Particularly in small-batch production with frequent product

changeovers, single-use systems offer an affordable alternative. But they are also well suited for large-volume filling and high-speed applications up to 400 containers per minute in multi-product lines, where conventional cleaning methods such as CIP/SIP not only cause extended downtimes but also aseptic risks due to several complex steps involving a lot of equipment. Because the components are disposed of after use, there is no need for cleaning, cleaning validation, or (re-) sterilization. Moreover, presterilized containers further reduce the number of processes and associated risks, because they no longer require the usual washer and depyrogenation tunnel for sterilization.

Cleaning and decontamination

Despite all discussions about barrier systems, there is at least one thing that RABS and isolators have always had in common: “after a batch is before a batch”. Cross-contamination and cleaning procedures play a decisive role, and the high requirements of aseptic production can only be fulfilled by thorough cleaning.

The vapourized hydrogen peroxide approach has been successfully used for 25 years as an additional surface sterilization method in aseptic manufacturing facilities worldwide. Vapourized hydrogen peroxide is vapoured, low concentrated hydrogen peroxide (e.g., 35%). A specially designed generator initially dehumidifies the ambient air, then produces vapourized hydrogen peroxide by passing aqueous hydrogen peroxide over a vapourizer and doses a certain concentration into the dedicated area; the system is fully controlled and monitored.

While vapourized hydrogen peroxide is used mainly in isolators, it can now also be seen in some closed-RABS (cRABS) applications, and it is by no means ruled out by Annex 1. The molecular structure of vapourized hydrogen peroxide can sterilize surfaces that may not be easily accessible with other cleaning agents, such as sporicides or isopropanol wipes. VHP is no substitution for well-performed general cleaning

Figure 3: Single-use liquid filling equipment, such as the PreVAS single-use system with peristaltic pump (Bosch Packaging Technology) can be used in either traditional vessels or fully disposable fluid handling technologies.



Next steps

A lot of what is described in Annex 1 is already common practice in many production facilities worldwide, including the use of automation, preventive maintenance, process monitoring, and extensive risk management. Risks must be identified; processes must be designed with common sense; and most importantly, the highest quality standards need to be established in daily working life. In the end, approval always depends on the ability to prove that the processes and technologies are safe for product, operator, and patients. At the same time, every guideline, procedure, or specification can only be as good as its application.

procedures or overall good aseptic processes. However, this additional surface sterilization will further reduce sterility risks in a risk analysis. Indirect contact parts, such as stopper bowls, still need to be sterilized (i.e., in an autoclave) before entering an isolator. They are usually

unwrapped and inserted immediately before a decontamination cycle under LF conditions or transferred immediately before production starts in the closed and decontaminated isolator. Microbiological monitoring provides additional confidence in these procedures.


Reference

1. European Commission, *EudraLex, Volume 4, EU Guidelines to Good Manufacturing Practice Medicinal Products for Human and Veterinary Use, Annex 1, Manufacture of Sterile Medicinal Products*, December 2017. **PTE**



You enhance health.
We enhance taste.

galenIQ™ – the sweet
filler-binder.



galenIQ™ is pharma-grade Isomalt (Ph. Eur., USP-NF, BP, JP).
The easy-to-use filler-binder that makes medicine taste better.

galenIQ™
a brand of beneo



Integrating Powder Characterization into Raw Material Selection and Process Optimization

As tests at GSK have shown, integrating powder testing into overall operations can optimize process understanding, and with it, raw material selection, equipment design, and process development.

Todd Mollner is global product owner at GSK's consumer health respiratory powders. **Jamie Clayton** is operations director at Freeman Technology.

The past few decades have brought radical change to the pharmaceutical and healthcare industries. Generic pharmaceuticals now account for 90% of prescriptions in the United States, and manufacturers in the US and Europe continue to outsource more of their strategic operations to service providers. As a result, global pharmaceutical supply chains, even for widely used treatments, have become increasingly complex. Managing these supply chains is challenging but crucial, particularly in light of ongoing drug shortages (1).

Maintaining product consistency and manufacturing relies on identifying multiple suppliers that can make active ingredients and excipients to required standards. Manufacturers must set a specification that defines those standards as a critical first step to ensuring and managing product quality. However, it is not unusual for an established specification to fail to capture an aspect of behaviour that results in poor performance during manufacturing. This article examines how powder testing can be integrated with manufacturing and quality operations to optimize raw material selection and process optimization, sharing results of some projects at GlaxoSmithKline (GSK).

Establishing powder specifications

Any supplier of a pharmaceutical raw material, excipient, or active ingredient must ensure that materials meet product specifications, which establish a basis for acceptance or rejection. For powders, however, materials may meet product specifications, and yet go on to perform differently in the manufacturing process. This usually occurs because the specification failed to capture some aspect of powder behaviour that is relevant to process performance.

Pharmaceutical manufacturers could get around this issue by challenging suppliers to meet more demanding specifications. However, this would likely drive up both raw material and, by extension, finished pharmaceutical costs. A smarter approach would be to develop a better understanding of material performance requirements, based on what is actually needed for the product, and then choose suppliers whose products best meet those needs.

Using powder characterization methods can provide better insight into material properties to help determine which of those properties are most critical to quality and which correlate most robustly with in-process behaviour and manufacturing efficiency.

Powder testing

Techniques for powder testing vary considerably in terms of sophistication, ease-of-use, sensitivity, and process relevance. *United States Pharmacopeia (USP) <1174> (2)* specifies the following techniques:

- Angle of repose
- Compressibility index/Hausner ratio
- Flow through an orifice
- Shear cell methods.

The first three techniques are simple methods that provide single number assessments of flow. Shear cell methods, developed in the 1960s, represent the first attempt to bring a more scientific approach to powder characterization.

These tests measure the force required to shear one consolidated powder plane relative to another. They were advanced to support a directly associated hopper design methodology and are widely used. Modern instrumentation has made the technique more accessible and reproducible via automated protocols and refined engineering design.

Shear cell testing is useful for assessing powders behaviour under the moderate-to-high stress conditions typically found in a hopper. It can be challenging to implement, however, and is not intuitive with respect to data use or interpretation. Furthermore, the method is less relevant to process applications where the powder is in a low stress or dynamic state, particularly when aerated or fluidized. As a result, many companies consider powder testing to be an expert task that must be handled by external consultants. This may be a pragmatic approach, but it can result in one-off solutions, rather than integrating powder testing into improving understanding of process behaviour for raw material selection and process optimization and troubleshooting.

To facilitate an integrated approach, powder testing methods and instrumentation should:

- Be easy to use
- Offer relatively high productivity

and deliver a good informational return on investment

- Provide data that correlate directly with process performance
- Measure with high sensitivity to provide effective differentiation.

Dynamic powder testing was developed specifically to meet industrial requirements for process relevant data. Dynamic properties are determined by measuring the axial and rotational forces that act on an impeller as it is precisely rotated through a powder sample, which may be consolidated, moderately stressed, aerated, or fluidized depending on the process and conditions of interest (see **Figure 1**). Instruments for dynamic testing also have the capability for shear and bulk property measurement and can therefore be used to generate a database of powder properties to determine the precise characteristics that define optimal performance in any given process.

GSK Consumer HealthCare has used dynamic testing methods to characterize powders that are routinely used in the production of a range of over-the-counter (OTC) pharmaceuticals. Results were incorporated into a database of specifications for all the materials used, enabling the evaluation of new suppliers and assessment of the consistency of established supplies. Data have also been used to establish correlations that define optimal processing parameters in processes such as tabletting and roller compaction, and more generally in process optimization and troubleshooting.

Roller compaction studies

One study of dynamic powder testing methods focused on the correlation between roller compaction and compressibility. Roller compaction, which converts fine powder blends to stable, more freely flowing granules, is used routinely to produce OTC respiratory powders. In this case, previous in-house studies had identified compressibility as a critical parameter for roller compactor performance. Compressibility quantifies change in bulk density (or volume) as a function of consolidation pressure (see **Figure 2**), with

Figure 1: Dynamic powder testing quantifies flowability and can be used to characterize powders in a consolidated, moderate stress, aerated, or fluidized state.





Figure 2: Compressibility quantifies change in volume and consequently bulk density, as a function of applied normal stress.



powders of higher compressibility requiring a greater compaction force to produce a stable ribbon in the compactor. Studies had been previously carried out to determine optimal processing parameters for feeds of varying compressibility.

One of the active ingredients used in this process typically has a compressibility of approximately 5%. Alternative supplies, all of which met market specifications, were identified and tested to assess their suitability for use in the process. One material was found to have a compressibility of 10% and was easily accommodated by changing processing parameters based on correlations and existing understanding. Another material was found to have a compressibility of 25%, which was somewhat surprising given all supplies had met the same specification. An attempt was made to process the high compressibility material to see whether granules could be produced. Given the need for a very high compaction force, it

was hypothesized that any resulting granules would be very hard. It proved impossible, however, to produce any granules at all with the existing equipment, because sufficient compaction force could not be generated to produce a stable ribbon. As this example shows, measuring the right powder property (in this case, compressibility) allows manufacturers to differentiate between materials that are available on the market. Even if they have all been manufactured to an existing specification, testing can determine which ingredients will and won't work well in any given process.

Robust process optimization

In the previous example, powder testing allowed manufacturers to incorporate process requirements into the raw materials selection process, so that they could easily reject material that would be most likely to cause a process failure. Powder testing can also be used to solve a more common problem:

Figure 3: Critical dimensions for a hopper include half angle (α) and outlet size (B).





Figure 4: A mass flow regime (A), in which all the powder moves together, is preferable to funnel flow (B) and the stagnation of powder against the hopper walls.



the gradual decline in process performance that can often be traced to use of suboptimal raw materials.

Often optimal material characteristics are not well understood, so when powder testing is available and accessible to those with processing expertise, it can be used to optimize existing processes, as the next two examples show. In this case, powder testing was performed to troubleshoot a problem that occurred when product was discharged: at low levels, the active ingredient would separate from

bulk materials, so, depending on its position in the hopper, the discharged product could contain more, or less, active ingredient than required. A certain amount of product was therefore discarded with each batch to safeguard product consistency.

The powder was tested, and results were processed through the instrument's integral hopper design software (3). Based on results, a new hopper was specified with a 55% larger volume and different design parameters, a different half angle and outlet size, as shown in **Figure 3**.

Video footage from within both hoppers verified a change in flow and the new design's superiority in delivering a better flow regime. The original hopper design induced funnel flow (**Figure 4**), a regime in which there is a central column of moving powder and static material at the hopper walls. This flow pattern can result in rolling segregation and associated powder interactions with the hopper. The new design, in contrast, maintains a desirable 'first-in, first-out' flow pattern with no edge effect until the vessel is completely emptied. Though the new hopper is larger than the original, it empties faster and eliminates the product waste associated with the old design, saving 8% in material costs

De-bottlenecking

In this case, powder testing was carried out to define specifications for a legacy tabletting process. The process had been running for many years, but, over time, throughput had been steadily eroding. Alternative raw material supplies were proving progressively more difficult to process, reducing tabletting rates by almost 50% over a number of years. In-house studies identified both compressibility and flowability as key parameters for the tabletting blends, allowing materials to be selected that could drive throughput back up to historical levels. In cases such as this, where throughput is increased by 50%, investment in inhouse testing equipment can return between 50 and 100 times its initial cost, delivering substantial return on investment.

References

1. S. Hoffmann, "Drug Shortages Pose a Public Health Crisis in the US," *theconversation.com*, www.theconversation.com/drug-shortages-pose-a-public-health-crisis-in-the-us-98295
2. USP, <1174> Powder Flow, USP-NF 28 (2), March 2002, www.usp.org/sites/default/files/usp/document/harmonization/genchapter/g05_pf_30_6_2004.pdf.
3. T. Freeman, "Modern Tools for Hopper Design," freemantech.co.uk, www.freemantech.co.uk/literature/white%20papers/Modern_tools_for_hopper_design-LAF205-E.pdf **PTE**



Planning a Successful API Procurement Strategy

Sourcing hard-to-find ingredients and establishing a reliable supply chain can stretch the resources of a small- to mid-size pharma company.

Selwyn Lustman is senior vice-president global sourcing and procurement; **Lina Cogan** is senior director of global sourcing and procurement; and **Hamilton J. Lenox** is senior vice-president, business development, all with LGM Pharma.

The age of “blockbuster” medicine, when the market was ruled by multibillion-dollar drug manufacturers producing a small number of products in large quantities, has begun to expire. With its decline comes a new, more complex marketplace that favours generic drugs over branded giants, personalized therapies over one-size-fits-all medicine, and novel formulations and drug delivery systems over traditional approaches.

The result is an increasingly diverse and more complex industry. Small- and mid-sized drug development companies are vying to offer differentiated and innovative drug products in a crowded market. Such innovation requires increasingly specialized and hard-to-find APIs. Small, lean companies that specialize in pharmaceutical development, not supply chain logistics, often struggle to source unique ingredients from manufacturers around the world under aggressive timelines and in quantities suitable for each stage of development.

Intensifying regulatory pressure adds to these challenges. Previously, regulatory authorities focused primarily on the purity and integrity of the drug product itself; today’s health authorities have extended their reach to incorporate a product’s entire chain of custody. In the United Kingdom, the Medicines and Healthcare products Regulatory Agency recently prioritized supply chain integrity in its five-year corporate plan (1). The European Commission’s November 2013 update to its *Guidelines on Good Distribution Practice of Medicinal Practice for Human Use* also reflects a drive toward global traceability. Also in November 2013, the US Congress enacted the Drug Supply Chain Security Act, giving the US Food and Drug Administration (FDA) enhanced abilities to enforce elevated trackability and product verification standards.

These guidelines demonstrate how regulators have extended oversight over the entire supply chain, leading to a higher incidence of compliance actions. The number of warning letters issued in the United States more than doubled between 2012 and 2016 (**Figure 1**).

Drug companies grappling with the challenges of API procurement must not only manage their own quality systems, but also must ensure the quality of their supply chain, including elements outside of their control. An API manufacturer with poor infrastructure or improperly applied standard operating procedures (SOPs) can introduce consequences for the entire drug development process, putting developers at risk for regulatory sanctions. Collectively, these challenges risk knocking even the most visionary drug development companies to the sidelines, struggling with

API quality, logistical issues, or the complications of regulatory approval.

By understanding the challenges involved in sourcing hard-to-find APIs, developing transparent and scalable manufacturer relationships either independently or with support from a qualified expert, and maintaining end-to-end regulatory approval, drug developers can avoid unforeseen quality, logistical, and regulatory roadblocks.

Looking for a niche API in a haystack

The 505(b)(2) accelerated drug approval pathway was enacted in the 1984 Hatch-Waxman Amendments of the US Federal Food, Drug, and Cosmetic Act to encourage innovation in the development of new formulations, indications, or delivery systems for existing active ingredients. Under the pathway, drug companies can use safety and efficacy information for APIs from studies of previously approved agents, allowing them to stretch the value of existing clinical knowledge and unlock novel drug applications.

Today’s startup culture—enabled by modern technology and a surge in expired patents and exclusivity agreements—is behind an increase in 505(b)(2) applications (**Figure 2**). This competitive move toward innovation provides consumers with more treatment options; however, drug companies pursuing the 505(b)(2) pathway may have difficulty finding small batches of hard-to-find ingredients for research activities.

Many large, established API manufacturers do not offer the modest quantities that 505(b)(2) innovator companies need to sustain R&D programmes. A less-established manufacturer may not have the infrastructure or expertise to produce an unfamiliar compound; developing that infrastructure takes capital that API manufacturers may not be willing or able to devote to a 505(b)(2) project, especially for a modest batch size.

Securing a hard-to-find API in a low volume requires an understanding of the current API manufacturing landscape. Subscription databases that track API-manufacturer capabilities and meetings at trade shows with API manufacturers may be cost-prohibitive for small players without in-house procurement capabilities.

Figure 1: Warning letters issued against drug establishments in the United States. Data source: FDA Data Dashboard as of 15 August 2019 (2).





Figure 2 : Number of 505(b)(2) approvals issued in the United States. Data source: GlobalData Intelligence Center (3).



Scaling up supplier support

A small drug company may be able to find a manufacturer to supply a small quantity—say 50 kg—of a niche API for efficacy and safety testing. After that testing is complete and the formulation has proven successful, the drug company must contact the API manufacturer for a larger order—perhaps 750 kg—to prepare for commercialization. The original batch size of 50 kg is too small; running 15 batches of that size would take too long and cost too much. A request to increase volume to five batches of 150 kg may not be readily met.

Companies that pre-qualified the API manufacturer by discussing scale-up

requirements early on are in a good position. The manufacturer has bought into the expected growth curve and has the spare capacity to fulfill orders through every developmental phase.

Those companies are in the minority. Due to competitive pressures, many companies focus on testing and shepherding their product through R&D. Few are aware of the proper questions to ask when negotiating future capacity with a manufacturer, which often results in unpleasant late-stage discoveries: the API manufacturer doesn't have the capacity to scale, or they do but only with additional instrumentation and validation. Suddenly, the whole project is at risk.

Finding the right partner to match the phase of development and grow with the developing drug is crucial and can be difficult, without specific expertise.

You cannot afford non-compliance. Period.

While a drug in development has unique API, batch size, and financial requirements, all companies face similar challenges with regulatory oversight and identifying compliant API manufacturers. Assuming a manufacturer is competent because it has a customer list can lead to a false sense of compliance.

Even more reassuring is a facility with a certificate of good manufacturing practice (GMP), which drug companies can research using databases such as the European Medicines Agency's EudraGMP or FDA's Inspection Classification Database Search.

Having customers—or holding a certification—should not be a threshold of quality assurance. Have those customers filed complaints? Is the certification out of date? Is the manufacturer fraudulently claiming the identity of a certified establishment? A regulator's inspection report is no guarantee of compliance; it's not a promise. It's just one of many factors to consider when developing a potential vendor's risk profile.

The other factors require more digging to uncover. This difficult task makes it tempting for a small company to believe that an aging GMP certificate guarantees compliance. Sometimes it does, but when it doesn't, the consequences can be catastrophic. The API could be snarled in importation paperwork, sustain damage from improperly controlled temperatures, or be out of specification when it arrives, rendering it unusable. These outcomes could lead to stalled production, expired patents, lost investment, and a shredded reputation. Such doomsday scenarios are rare; however, digging—or due diligence—can eliminate the possibility of catastrophe.

It's likely not possible to visit every potential manufacturer; digging comes down to asking the right questions early and from afar. What SOPs are in place to ensure proper cleaning and sterilization in the facility? How are temperature specifications determined and controlled? How are products

labelled? How are they transported and stored? How are rodents and other pests eliminated? How are staff trained and evaluated? How are deviations and complaints handled? What software is used and is it validated? How are data backed up and how often?

These questions are not about the manufacturing process per se, but rather about the ancillary systems that support it. These systems make up a manufacturer's holistic quality management protocol, and together paint a picture of that manufacturer's integrity. The best way to ensure that a product will arrive a high-quality, compliant compound with a transparent chain of custody is to do this digging or hire an expert to do it. The cost may pinch at first, but better the discomfort of a pinch today than the knock-out punch of catastrophe later.

Proceed with caution

It's hard to move fast in the drug development space, even on the 505(b)(2) pathway. Pre-qualifying a manufacturer for a specialized, low-

volume API supply can slow down the process. Moving APIs from another global location to a facility takes domain expertise, experience with regulatory protocols, and access to the right players at the right time. Regulators will inspect every node in the chain of custody; drug companies must know that chain well and trust it completely.

Drug companies with large in-house sourcing and procurement teams can perform these functions internally. Smaller companies—operating without such a team—should follow this piece of advice: find a way to become, to hire, or to partner with a supply chain expert.

Becoming a supply chain expert will require time, which must be siphoned away from the original purpose of developing a novel drug therapy. Hiring an internal sourcing team is a good option, if that bandwidth is available. For most companies, partnering with an API procurement and supply chain expert is the most cost-effective route, particularly if that expert has a strong quality assurance programme and incorporates on-site

audits as part of its assessment criteria. These are specialists that understand regulations and have strong manufacturer relationships around the globe, which means small companies can negotiate like big ones, and those new to regulatory scrutiny are assured of continuous compliance.

Whatever the chosen approach, the key is to obsess over every detail throughout the supply chain, leaving nothing to chance, and taking no manufacturer's assurance of competence or integrity at face value. Don't gamble the success of an innovative new drug on a suspect supply chain; trust API procurement to those with the expertise to manage it.

References

1. Medicines and Healthcare products Regulatory Agency, Corporate Plan 2018–2023 (24 April 2018).
2. FDA, Compliance Data Dashboard, <https://datadashboard.fda.gov>, accessed 15 August 2019.
3. GlobalData, Intelligence Center, globaldata.com. **PTE**

Objective and reliable expert editorial coverage in the bio/pharmaceutical industry *since 1989!*

- Process Development
- Manufacturing Trends
- Formulation
- Analytical Technology Regulatory
- Compliance Quality Assurance
- API synthesis
- Packaging and Outsourcing
- Industry Best Practices



Sign up for a FREE print or digital subscription today
pharmtech.com/subscribe-pharmtech



Market Dynamics Drive the Agenda for CPhI Worldwide

New therapies, new technologies, global supply chain challenges, and political pressures draw pharma professionals to major industry event.

The editors of
Pharmaceutical Technology Europe

Emerging therapies, business and political stresses, aging facilities, supply chain transparency, and regulatory oversight are some of the issues the bio/pharma industry currently faces. Mergers and acquisitions on both the pharma and supplier sides of the market, pricing pressures for innovator and generic drugs, new technologies including artificial intelligence and the industrial Internet of Things, the globalization of supply chains, and rise of digital medicine are factors shaping decision making in the bio/pharma laboratory, manufacturing plant, and boardroom.

With complex issues facing the pharma industry, decision makers charged with developing and delivering drugs to market will gather in Frankfurt, Germany on 5–7 November 2019, for the annual CPhI Worldwide trade show.

The event, which in 2018 attracted more than 44,000 bio/pharma industry professionals from 165 countries to visit more than 2500 exhibiting companies, is an opportunity to meet with business contacts, learn about new technologies, and network with other drug development and manufacturing professionals in the industry (1). A review of the proposed 2019 agenda reveals the event will address key topics facing the pharma industry.

The exhibits and conference programme at CPhI represent a cross-section of bio/pharmaceutical development and manufacturing functions. Visitors work for a range of pharma business types including generic finished products pharmaceutical companies (16%), innovator finished products pharmaceutical companies (9%), contract service providers (15%), and distributors (14%). API producers, over-the-counter drug companies, nutraceuticals, pharmacy, academic, and other organizations round out the audience (1).

The 2019 event at the Messe Frankfurt exhibition centre in Germany will feature six events for APIs, excipients, and other ingredients (CPhI); contract services (ICSE); packaging (InnoPack); finished drug products (FDF); equipment (P-MEC); and bioprocessing (BioProduction), which are accessible through one visitor pass. A matchmaking service pairs buyers of bio/pharma ingredients, equipment, and services with

exhibitors offering those products and services for onsite meetings. Free-to-attend conference programmes include Insight Briefings, a World of Pharma Podium, and Natural Extracts Podium. (See sidebar on page s40.)

In addition, event organizers will recognize innovation in development, manufacturing, distribution, and business in the pharmaceutical industry at the annual CPhI Pharma Awards ceremony.

M&A reshape bio/pharma dynamics

Following a trend of previous years, mergers and acquisitions—both announced and finalized—look to change the composition of the pharma industry and may shift the way bio/pharma companies conduct research, development, and manufacturing, key considerations for visitors to CPhI Worldwide. Through the first half of 2019, both innovator and generic-drug companies announced deals to reposition their drug portfolios, strengthen their financial positions, or enter the emerging cell- and gene-therapy arenas.

Bristol-Myers Squibb's (BMS's) planned acquisition of Celgene will create a combined company with an early-stage pipeline of 50 potential therapies; BMS also sold its UPSA consumer health business to Taisho Pharmaceutical Holdings in July 2019.

AbbVie's acquisition of Allergan, announced in June 2019, was positioned as a move to reduce reliance on Humira—which is scheduled to lose patent exclusivity in 2023—and expand the company's focus to other therapeutic areas.

In August 2019, Bayer announced an agreement to divest its animal health business to Elanco Animal Health and acquire cell-therapy development company BlueRock Therapeutics in an effort to focus on life sciences.

Other major transactions announced or completed in 2019 include Pfizer (Array BioPharma and Therachon), Merck & Co. (Peloton Therapeutics and Tilos Therapeutics), Biogen (Nightstar Therapeutics), GlaxoSmithKline (Tesar), Eli Lilly (Loxo Oncology), and Takeda Pharmaceutical (Shire).

CPhI Worldwide 2019 Schedule as of 26 August 2019.

Time	Activity	Location
Tuesday, 5 November 2019		
9:30–17:30	Exhibition Open	Messe Frankfurt
9:50–15:40	BioProduction Presentations	BioProduction Theatre: Hall 12
10:30–16:60	Pharma Insight Briefings	CPhI Theatre: Hall 6 ICSE Theatre: Hall 12 InnoPack and P-MEC: Hall 11
11:00–15:30	Natural Extracts Podium	Hall 4
11:00–16:15	World of Pharma Podium	Hall 8
Wednesday, 6 November 2019		
9:30–17:30	Exhibition Open	Messe Frankfurt
9:50–15:40	BioProduction Presentations	BioProduction Theatre: Hall 12
10:30–16:60	Pharma Insight Briefings	CPhI Theatre: Hall 6 ICSE Theatre: Hall 12 InnoPack and P-MEC: Hall 11
11:00–15:30	Natural Extracts Podium	Hall 4
11:00–16:15	World of Pharma Podium	Hall 8
15:30–17:30	M&A Forum	Hall 4, Entrente Room
15:30–18:30	Women in Leadership Forum	Frankfurt Marriott
Thursday, 7 November 2019		
9:30–16:00	Exhibition Open	Messe Frankfurt
9:50–13:45	BioProduction Presentations	BioProduction Theatre: Hall 12
10:30–13:00	Pharma Insight Briefings	CPhI Theatre: Hall 6 ICSE Theatre: Hall 12 InnoPack and P-MEC: Hall 11

View www.cphi.com/europe for schedule updates. All activities are at the Messe Frankfurt, unless noted.

Supplier-side acquisitions and expansions

The corporate restructuring of bio/pharma companies has implications for the supplier side of the market, which also witnessed announcements of business changes. Two prominent deals included moves by contract development and manufacturing organizations (CDMOs) to play significant roles in the cell- and gene-therapy markets.

In May 2019, Catalent (Stand 121A82, ISCE) completed a €1.08 billion (US\$1.2 billion) acquisition of Paragon Bioservices, a viral vector development and manufacturing company for gene therapies with expertise in adeno-associated virus vectors (2). In July, the company completed the purchase of vaccine manufacturing equipment and facility assets and assumed the leases of two Novavax product development and manufacturing facilities (3).

Also in May, Thermo Fisher Scientific (Stand 121C80, ISCE) purchased Brammer Bio, a gene-

and cell-therapies CDMO, for approximately €1.53 billion (US\$1.7 billion) in cash. The acquisition will become part of Thermo Fisher's Pharma Services business (4).

Other deals involved the transfer of manufacturing assets from bio/pharma companies to contract manufacturers, signalling a shift to outsourcing of key development and manufacturing functions.

In August, Fujifilm Diosynth Biotechnologies (80B84, CPhI/Integrated Pharma Zone) acquired the Biogen Manufacturing ApS facility near Copenhagen, Denmark, adding a large-scale production facility with six 15,000-L bioreactors; an assembly, labelling, and packaging facility; and quality control laboratories and warehouses. Separately, the company announced a US\$10-million investment to establish an integrated continuous processing facility for non-GMP biopharmaceutical manufacturing—including a 500-L single-use perfusion bioreactor and seven downstream processing units—at its Billingham, UK, location in June.

In June, Catalent announced that it agreed to purchase Bristol-Myers Squibb's oral solid, biologics, and sterile product manufacturing and packaging facility in Anagni, Italy (5).

The company also announced an expansion of its global spray drying capacity through an agreement with Sanofi Active Ingredient Solutions, which gives Catalent access to spray drying manufacturing equipment at Sanofi's Haverhill, UK, facility. Furthermore, the company said it will invest up to €36.1 million (US\$40 million) at its manufacturing facility in Winchester, KY, USA to increase the site's formulation and controlled-release tablet and capsule manufacturing capabilities and capacity (6). In July 2019, Catalent Biologics started construction on a €101 million (US\$112 million) packaging facility that includes vial, bulk filling, and syringe/cartridge lines (7).

Lonza Pharma & Biotech (Stand 121C10, ICSE) announced on 1 July 2019 an agreement to purchase a sterile drug product fill and finish facility in Stein, Switzerland from Novartis. The facility

will be the first sterile product finish and fill facility in Lonza's network for clinical supply and commercial launch (8). In addition, Lonza announced plans to add two highly potent API (HPAPI) production lines at its Visp, Switzerland site including the addition of two multi-purpose lines to the company's existing capabilities for lab-scale to large commercial-scale HPAPI production (9).

In May, Thermo Fisher Scientific announced an agreement to acquire a GlaxoSmithKline drug

substance manufacturing site in Cork, Ireland for approximately €90 million (US\$100 million). The site contains 270 cubic metres of reactor capacity, 10 production buildings, an R&D pilot plant, and lab infrastructure to support process development, scale-up, and physical characterization of APIs (10). The company also plans to invest €135.3 million (US\$150 million) at sites in Monza and Ferentino, Italy, and Greenville, NC, USA, to

add capacity for sterile liquid and lyophilized product development and commercial manufacturing (11).

Contract services restructuring and refocusing

With the ongoing consolidation of bio/pharma companies, as well as pressure to get products to market faster, more drug development and manufacturing companies are turning to contract service providers for support of formulation, development,

Conference Programme Addresses Industry Topics

Visitors to CPhI can attend informational sessions presented by industry experts and sponsors. Key sessions as of 26 August 2019 are highlighted below. For a complete list of sessions, visit www.cphi.com/europe/agenda.

Exploring Trends in Contract Manufacturing

Tuesday, 5 November 2019, 10:30–11:40

ICSE Theatre, Hall 12

As pharma evolves toward complex therapies with specific manufacturing needs, the role of the contract development and manufacturing organizations (CDMOs) has never been so important. With efficiency, cost, flexibility, and quality essential components of outsourcing, how are CDMOs evolving to remain competitive? Which technologies and strategies will provide the biggest returns?

The Future of Medicine: What Are the Therapies of Tomorrow?

Tuesday, 5 November 2019, 10:30–11:40

CPhI Theatre, Hall 6

Oncology, auto-immune, cardiovascular, pulmonary, and mental health are all key therapy areas for Pharma companies. This panel will examine emerging therapies for the future pharma toolkit—both developing the new and repurposing the old.

Trends in Sustainable Pharma Packaging and Drug Delivery Devices

Tuesday, 5 November 2019, 10:30–11:40

InnoPack and P-MEC Theatre, Hall 11

Understanding Cell and Gene Therapy Opportunity

Wednesday, 6 November 2019, 10:30–11:40

ICSE Theatre, Hall 12

Cell and gene therapies provide treatment solutions to patients with previously unmet needs, and with regulators ready for an influx of product approvals in the coming years, the sector offers a significant commercial opportunity. This panel will discuss the investment opportunity for those looking to enter this ever-evolving sector.

Global Outlook: The Future of Biosimilars

Wednesday, 6 November 2019, 10:30–11:40

CPhI Theatre, Hall 6

Biosimilars are an indispensable tool for providing patient access to innovative, effective therapies whilst keeping healthcare costs sustainable. This panel will assess the global outlook: Europe's reasonably mature market, new Asian players, and the challenges to adoption in the United States.

Improving Patient Compliance and Adherence through Packaging/Device Innovations

Wednesday, 6 November 2019, 10:30–11:40

InnoPack and P-MEC Theatre, Hall 11

Made to Order: 3D Printing for Personalized Medicines

Thursday, 7 November 2019, 10:30–11:40

ICSE Theatre, Hall 12

As the Pharma industry shifts from volume to value, addressing smaller patient populations and orphan diseases, 3D printing technologies have a transformational role to play. With the promise of increasingly personalized and sophisticated solutions that offer significant benefits in terms of formulation, solubility, and controlled release, what does the future hold?

AI for Drug Discovery

Thursday, 7 November 2019, 10:30–11:40

CPhI Theatre, Hall 6

The process for drug discovery and development is changing as finding viable new drug targets becomes increasingly complex. Artificial intelligence (AI), or machine learning, has been touted as a solution for helping drug development teams overcome challenges with data analysis. This discussion will provide an overview of the current state of play and the future potential of AI for Pharma.

Trends in Packaging and Devices for Biologics

Thursday, 7 November 2019, 10:30–11:40

InnoPack and P-MEC Theatre, Hall 11

Podium and forum presentations

Developments in different regions and key issues facing the pharma will be addressed in sessions at the World of Pharma Podium (80B10). Topics include leadership in pharma, oncology therapies innovation, the healthcare digital wave, and the regulatory outlook. Regional topics include Brexit, the US market for cell and gene therapies, and opportunities in Africa and the Middle East, China, Japan, Korea, and India.

Other educational opportunities include discussions at the Natural Extracts Podium (Hall 4), a Mergers & Acquisitions Forum, a Women in Leadership Forum (separate fee required), keynote sessions, panel discussions, presentations, and tours as part of the BioProduction event (BioProduction Theatre, Hall 12).

manufacturing, packaging, and distribution of innovator and generic drug products. The ICSE section of CPhI, located in Hall 12, will host more

than 265 contract service providers, including analytical laboratories, clinical trial services, research services, formulation experts,

manufacturers, and packaging services. In addition to meeting with current or potential suppliers, visitors to CPhI can hear panel

Featured CPhI Worldwide exhibitors

More than 2500 companies will showcase ingredients, materials, equipment, instruments, and services at CPhI Worldwide on 5–7 November 2019 in Frankfurt, Germany.

CPhI/API Zone

Cambrex, Stand 41C10

Cambrex provides drug substance, drug product, and analytical services for small-molecule drugs. The company acquired Avista Pharma in early 2019 and announced multiple expansions at facilities in Europe and North America during the past year. On 7 August 2019, Cambrex signed an agreement to be acquired by an affiliate of Permira, a global investment firm.

Novo Nordisk, Stand 42D32

Novo Nordisk Pharmatech supplies ingredients for the biopharmaceutical and pharmaceutical industries including recombinant insulin for cell growth media and pharmaceutical-grade quaternary ammonium compounds manufactured to cGMP standards. The company's quality system meets DS/EN ISO 9001 and ICH Guide Q7 for active pharmaceutical ingredients.

CPhI/Excipients Zone

Beneo, Stand 102C11

Beneo offers galenIQ, a range of water-soluble filler-binders that can be used for tablets, sachets, lozenges, and syrups. Derived from beet sugar, the product has a sweet taste, making it suitable for solid and liquid oral applications and with active ingredients that have a bitter or unpleasant flavour. The excipient is manufactured under cGMP conditions according to IPEC-PQG requirements for pharmaceutical excipients.

Colorcon, Stand 102B70

Colorcon develops, supplies, and provides formulation support for oral solid dose drugs. The company offers formulated film coating systems, modified-release technologies, and functional excipients backed by application data and value-added services. In addition, the company offers colour customization support to create a unique tablet image to specifications. In July 2019, the company announced plans to build a new starch manufacturing plant near Amsterdam.

CPhI/Integrated Pharma Zone

BASF, Stand 80K40

BASF offers solutions for creates solutions for instant- and modified-release, solubilization, soft-gels, skin-delivery, and biologics using its polymer chemistry and R&D-capabilities. The company offers high-quality raw materials for production of APIs with a portfolio that includes solvents, building blocks, reagents, and protective groups.

Taiwan Pharmaceutical Alliance, Stand 80B50

Taiwan Pharmaceutical Alliance (TPA) comprises Taiwan-based API and generic-drug manufacturers. Products include metered-dose and dry-powder inhalers, liposome and microsphere injectables, high-potent soft gels, osmotic-controlled release oral delivery system tablets, eye drops, and biosimilars. TPA can provide contract development and manufacturing services, license in/out, and trading services.

ICSE

Grifols International, Stand 121C70

Grifols International offers contract development and manufacturing platform for sterile solutions and lipid emulsions with a long-term experience in producing intravenous solutions for the pharmaceutical industry worldwide.

Hermes Pharma, Stand 120D81

Hermes Pharma develops and manufactures user-friendly oral dosage forms, offering customized solutions from the development of new product concepts and formulations to manufacturing and regulatory support. The company produces effervescent tablets, orally disintegrating granules, chewable tablets, instant drinks, and lozenges.

Pharmaceutical Technology Europe, Stand 120F42

Pharmaceutical Technology Europe reports on developments in European pharmaceutical/biopharmaceutical development, manufacturing, and quality assurance and control. Visit Stand 120F42 to sign up for a free subscription, meet the editors, and learn about ways to contribute.

BioProduction

Sartorius Stedim Biotech, Stand 120F17

Sartorius Stedim offers biomanufacturing solutions for early-phase development through scale-up to commercial manufacturing. Technology offerings include single-use bioprocess engineering, bioreactors, filtration and purification, process control, and media and buffers. The company's bioprocess teams will be at CPhI to discuss process development and manufacturing requirements.

Innopack/P-MEC

Gerresheimer, Stand 111B10

Gerresheimer provides pharmaceutical packaging and products for the safe, simple administration of medicines including insulin pens, inhalers, prefillable syringes, injection vials, ampoules, bottles and containers for liquid and solid medicines with closure and safety systems as well as packaging for the cosmetics industry.

Röchling Medical Neuhaus, Stand 111D20

Röchling Medical produces pharmaceutical primary packaging solutions, components and delivery systems including oral, nasal, parenteral, transdermal, ophthalmic, and pulmonary devices, as well as application aids and system solutions for the simple and safe dosing and administration of drugs.

GEA Process Engineering NV, Stand 110C70

GEA offer process equipment for a variety of products, including oral solid-dosage forms, semi-solids, parenterals, and sterile liquids. The company—which provides process equipment for batch and continuous tablet production, contained materials handling, fermentation, separation and lyophilization—will offer hands-on demonstrations for batch and continuous production equipment.

discussions about trends in contract manufacturing, cell and gene therapy opportunities, and 3-D printing for personalized medicines at the ICSE Theatre in Hall 12. Insight Briefings will address analytical, formulation, and manufacturing functions, as well as sterilization, lyophilization, injectables and highly potent drugs, inhalation drugs, vaccines, and drug/device combinations.

Faster to market in a global supply chain

Increased demand for generic drugs is pressuring companies to deliver more product at lower prices. At the same time, regulatory authorities are stepping up oversight to ensure quality. In 2018–2019, recalls of angiotensin II receptor blockers due to impurities detected in the API were a leading story. As regulatory authorities scrambled to identify affected medicines, quality of the drug-ingredient supply, as well as supply chain transparency were questioned.

The scope of manufacturing and materials requirements for orphan drugs are different compared with blockbuster drugs. Shorter approval cycles reduce the amount of time available for process development and validation, sourcing material suppliers, analytical method development, establishing quality programmes, and securing supply chains.

Several zones at CPhI Worldwide host exhibitors and conference programmes to meet pharma company needs for ingredients, processing equipment, packaging, and finished dose formulations.

The CPhI segment of the event in Halls 4, 6, 8, 9, and 10 hosts more than 1275 manufacturers and suppliers of APIs, excipients, fine chemicals and intermediates, natural extracts, custom manufacturing, and integrated pharma. For generic drug manufacturing, the FDF section in Hall 9 features more than 450 suppliers in the finished dosage supply chain including Big Pharma, contract manufacturers, out-licensing specialists, end-product distributors, and end-user agents.

In addition to the exhibits, free educational sessions include panel discussions on the therapies of tomorrow, the future of biosimilars, and artificial intelligence for drug discovery.

Topics scheduled for Insight Briefings at the CPhI Theatre in Hall 6 include opportunities in emerging markets and China, data integrity, quality by design, biomolecule purification, and novel excipients. Other sessions will examine dry powder inhalation, cannabis-based drug development, plant-based ingredients, amorphous silica gel, bioavailability enhancement, and oligonucleotide manufacturing.

Manufacturing equipment is showcased in the P-MEC section in Hall 11, which also features LABWorld, a zone focusing on laboratory equipment and analytical biotechnology. InnoPack, also in Hall 11, features pharmaceutical packaging innovations. Panel discussions at the InnoPack–P-MEC Theatre will cover trends in sustainable pharma packaging and drug delivery devices, packaging and devices for biologics, and improving patient compliance and adherence through packaging/device innovations. Other topics include polymers for container closure systems, plastic vials and syringes, high viscosity/high volume drugs, pre-fillable syringes, particulate analysis, and new packaging and closure options.

Beyond small-molecule drugs

As blockbuster monoclonal antibody drugs mature and biosimilars come to market, suppliers are challenged to improve processing systems. At the same time, the emergence of cell and gene therapies are generating research and investment excitement. Development, manufacturing, and approval challenges are significant. In addition, pricing and reimbursement issues may hinder patient access to these therapies.

To address the challenges for biologic-drug manufacturers, the BioProduction show, with more than 50 exhibitors in Hall 12, will feature exhibits and conference sessions.

Attending CPhI Worldwide

The scope of CPhI Worldwide requires advance planning to enable visitors to maximize their time at the event. The event organizers offer three registration packages: Visitor, VIP, and VIP Exclusive. Registration, travel, hotel, Visa information, and other details about attending the event can be found at www.cphi.com/europe.

References

1. CPhI, *Post Show Report 2018*.
2. Catalent, "Catalent Completes Acquisition of Gene Therapy Leader Paragon Bioservices, Inc. for US\$1.2 Billion," Press Release, 20 May 2019.
3. Catalent, "Novavax and Catalent Announce Closing of Strategic Partnership," Press Release, 31 July 2019.
4. Thermo Fisher Scientific, "Thermo Fisher Scientific to Acquire Brammer Bio, a Leader in Viral Vector Manufacturing," Press Release, 24 March 2019.
5. Catalent, "Catalent to Purchase Bristol-Myers Squibb Manufacturing Facility in Anagni, Italy," Press Release, 19 June 2019.
6. Catalent, "Catalent Extends Global Commercial Spray Drying Capabilities in Europe," Press Release, 9 July 2019.
7. *Pharmaceutical Technology*, "Catalent Breaks Ground at US\$112-Million Drug Product Manufacturing Facility," www.pharmtech.com, 17 July 2019.
8. Lonza, "Lonza to Acquire Sterile Fill and Finish Facility from Novartis," Press Release, 1 July 2019.
9. Lonza, "Lonza to Expand HPAPI Development and Manufacturing Capacity," Press Release, 13 June 2019.
10. Thermo Fisher Scientific, "Thermo Fisher Scientific to Acquire Manufacturing Site in Cork, Ireland, from GSK," Press Release, 16 May 2019.
11. Thermo Fisher Scientific, "Thermo Fisher Scientific to Invest US\$150 Million to Expand Pharma Services Capabilities," Press Release, 18 March 2019. **PTe**

Ad Index

COMPANY	PAGE
BENEO GMBH	s31
CATALENT PHARMA SOLUTIONS	s44
COATING PLACE	s25
CORDEN PHARMA	
INTERNATIONAL GMBH	s43
EMERGENT BIOSOLUTIONS	s15
HERMES ARZNEIMITTEL GMBH	s19
MILLIPORESIGMA	s2
NOVO NORDISK	
PHARMATECH A/S	s11
VELTEK ASSOCIATES	s7



FULL-SERVICE CDMO >>
FOR A GLOBAL MARKET



PEPTIDES,
LIPIDS &
CARBOHYDRATES



HIGHLY POTENT
& ONCOLOGY



INJECTABLES



SMALL
MOLECULES




ANTIBIOTICS

MEET US AT

CPhI Worldwide
Stand 8.0N10
November 5-7, 2019
Frankfurt, Germany

www.cordenpharma.com



SOLVING BIOAVAILABILITY IS SCIENCE. DESIGNING TREATMENTS IS ART.

Successful formulations for better bioavailability are built on robust science, superior technologies and the art of drug design.

Catalent's expertise in solving thousands of solubility challenges with the broadest toolkit of formulation and delivery technologies, coupled with integrated screening, clinical manufacturing and supply, will help get your molecules into clinic faster, turning your science into reality. **Catalent, where science meets art.**

Catalent®